Association between human papillomavirus and primary lung cancer – a systematic review and pilot study by Karnosky, Julia
 
 
 
 
 
AUS  DEM LEHRSTUHL 
FÜR INNERE MEDIZIN II 
PROF. DR. MED. L. MAIER 
DER FAKULTÄT FÜR MEDIZIN 
DER UNIVERSITÄT REGENSBURG 
 
 
 
 
 
 
Association between human papillomavirus and primary lung cancer –  
a systematic review and pilot study 
 
 
 
 
 
Inaugural – Dissertation 
zur Erlangung des Doktorgrades 
der Medizin 
 
 
 
der 
Fakultät für Medizin 
der Universität Regensburg 
 
 
 
 
vorgelegt von  
Julia Karnosky 
 
 
 
 
 
 
 
 
 
2020 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
„
 -
 F
 r
 e
 i
 s
 e
 i
 t
 e
 -
 „
 
  
 
 
 
 
AUS DEM LEHRSTUHL 
FÜR INNERE MEDIZIN II 
PROF. DR. MED. L. MAIER 
DER FAKULTÄT FÜR MEDIZIN 
DER UNIVERSITÄT REGENSBURG 
 
 
 
 
 
 
Association between human papillomavirus and primary lung cancer –  
a systematic review and pilot study 
 
 
 
 
 
Inaugural – Dissertation 
zur Erlangung des Doktorgrades 
der Medizin 
 
 
der 
Fakultät für Medizin 
der Universität Regensburg 
 
 
 
 
vorgelegt von  
Julia Karnosky 
 
 
 
 
 
 
 
 
 
2020 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dekan:      Prof. Dr. Dr. Torsten E. Reichert 
 
1. Berichterstatter:     Prof. Dr. med. Christian Schulz 
 
2. Berichterstatter:     Prof. Dr. med. Matthias Evert 
 
Tag der mündlichen Prüfung:  13.07.2020 
 
 
 
 - 1 - 
 
1. Table of Contents 
1. Table of Contents ............................................................................................................................ - 1 - 
2. Abbrevations ................................................................................................................................... - 3 - 
3. Summary (Zusammenfassung) ........................................................................................................ - 5 - 
3.1 Fragestellung ............................................................................................................................. - 5 - 
3.2 Methoden ................................................................................................................................... - 5 - 
3.3 Ergebnisse ................................................................................................................................. - 7 - 
3.4 Schlussfolgerung ....................................................................................................................... - 9 - 
4. Introduction ................................................................................................................................... - 10 - 
4.1 Epidemiology .......................................................................................................................... - 10 - 
4.2 Lung Cancer ............................................................................................................................ - 11 - 
4.3 Etiology ................................................................................................................................... - 13 - 
4.4 Human Papillomavirus ............................................................................................................ - 14 - 
4.5 HPV and Cervical Cancer ....................................................................................................... - 16 - 
4.6 HPV and other Organ Sites ..................................................................................................... - 17 - 
5. Materials and Methods .................................................................................................................. - 18 - 
5.1. Meta-analysis ......................................................................................................................... - 18 - 
5.1.1 Literature Research ........................................................................................................... - 18 - 
5.1.2 Acquisition of Publications .............................................................................................. - 19 - 
5.1.3 Data Selection ................................................................................................................... - 20 - 
5.1.3.1 Inclusion Criteria ........................................................................................................... - 20 - 
5.1.3.2 Exclusion Criteria .......................................................................................................... - 21 - 
5.1.4 Data Extraction ................................................................................................................. - 21 - 
5.2 Experimental Part .................................................................................................................... - 22 - 
5.2.1 Biopsy Material ................................................................................................................ - 22 - 
5.2.2 HPV Detection ................................................................................................................. - 22 - 
5.3 Statistical Analysis .................................................................................................................. - 23 - 
 - 2 - 
 
6. Results ........................................................................................................................................... - 24 - 
6.1 Meta-analysis .......................................................................................................................... - 24 - 
6.1.1 Databank Research ........................................................................................................... - 24 - 
6.1.2 General Literature Research ............................................................................................. - 24 - 
6.1.3 Overview of the Literature ............................................................................................... - 26 - 
6.1.4 Patients Characteristics ..................................................................................................... - 27 - 
6.1.5 Continents ......................................................................................................................... - 29 - 
6.1.5.1 Europe ........................................................................................................................... - 29 - 
6.1.5.2 Asia ................................................................................................................................ - 34 - 
6.1.5.3 The Americas ................................................................................................................ - 39 - 
6.1.5.4 Continents compared ..................................................................................................... - 43 - 
6.1.6 Squamous Cell Carcinoma vs. Adenocarcinomas ............................................................ - 44 - 
6.1.7 Cases vs. Controls ............................................................................................................ - 45 - 
6.1.8 FFPE vs. fresh frozen ....................................................................................................... - 46 - 
6.1.9 1990s vs 21st century ........................................................................................................ - 47 - 
6.2 Experimental Part .................................................................................................................... - 48 - 
6.2.1 Patient Characteristics ...................................................................................................... - 48 - 
6.2.2 HPV Detection ................................................................................................................. - 50 - 
7. Discussion ..................................................................................................................................... - 51 - 
8. Conclusion ..................................................................................................................................... - 68 - 
9. Table of illustrations ...................................................................................................................... - 71 - 
9.1. Pictures ................................................................................................................................... - 71 - 
9.2 Tables ...................................................................................................................................... - 72 - 
10. Appendix ..................................................................................................................................... - 73 - 
11. References ................................................................................................................................... - 89 - 
 
 - 3 - 
 
2. Abbreviations  
 
- AC = adenocarcinoma 
- ALK = anaplastic lymphoma kinase 
- BRAF = v-Raf murine sarcoma viral oncogene homolog B1 
- CDKN2A = TP53 and cyclin-dependent kinase inhibitor 2A 
- CIN = cervical intraepithelial neoplasia 
- COPD = chronic obstructive pulmonary disease 
- DDR2 = discoidin domain receptor 2 
- E = early region of HPV genome 
- EBC = exhaled breath condensate 
- EBUS = endobronchial ultrasound 
- EGFR = epidermal growth factor receptor 
- EML4-ALK = echinoderm microtubule associated protein-like protein 4 fused with 
Anaplastic Lymphoma Kinase 
- FFPE = formalin-fixed paraffin-embedded 
- FGR1 = fibroblast growth factor receptor 1 
- HNSCC = head and neck squamous cell carcinoma 
- HCC = hepatocellular carcinoma 
- HPV = Human Papillomavirus 
- ISH = In situ hybridization 
- KRAS = Kirsten rat sarcoma viral oncogene homolog 
- L = long region of HPV genome 
- LC = lung cancer 
- LCR = long control region of HPV genome 
- MET = mesenchymal-epithelial transition factor 
- MOOSE = Meta-analysis of Observational Studies in Epidemiology 
- NSCLC = non-small cell lung cancer 
- OS = overall survival 
- PIK3CA = phosphoinositide-3-kinase catalytic subunit alpha isoform 
- PTEN = phosphatase and tensin homolog 
- PCR = Polymerase chain reaction 
- PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
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- PROSPERO = International prospective register of systematic reviews 
- RET = rearranged during transfection 
- ROS1 = c-ros oncogene 1 
- SCLC =  small cell lung cancer 
- SCC = squamous cell carcinoma 
- SOX2 = SRY related HMG box gene 2 
- TP53 = tumor suppressor protein 53 
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3. Summary (Zusammenfassung) 
 
3.1 Fragestellung 
 
Im Jahr 1979 haben Syrjänen et al. erstmals über einen möglichen Zusammenhang zwischen 
einer HPV Infektion und der Entwicklung von Bronchialkarzinomen berichtet. Im weiteren 
Verlauf wurden zahlreiche Studien mit unterschiedlichsten Detektionsmethoden durchgeführt. 
In diesen zeigten sich sowohl geographische Unterschiede, als auch Unterschiede, welche auf 
die verwendete Analysemethode zurückgeführt wurden. 
Ziel dieser Arbeit ist es, zum einen den aktuellen Stand in der Literatur bezüglich HPV 
Detektion mittels PCR in Lungenkrebsgewebe zu erfassen und zum anderen, dies mit den 
Ergebnissen unserer eigenen Kohorte zu vergleichen. 
 
3.2 Methoden 
 
Mittels einer strukturierten Literatursuche wurde zunächst versucht alle Publikationen zu 
erfassen, welche sich dem beschriebenen Thema widmen. Eine Einschränkung bezüglich des 
Publikationszeitraums oder der Sprache, in welcher die Publikation verfasst wurde, erfolgte 
nicht. Die erfassten Studien wurden anhand ihres Titels und, soweit verfügbar, Abstracts von 
zwei unabhängigen Personen begutachtet. Bei Uneinigkeit wurde die Entscheidung durch eine 
dritte Person getroffen. Anschließend wurde von allen eingeschlossenen Publikationen die 
Volltextversion beschafft und hinsichtlich der Ein- und Ausschlusskriterien geprüft.  
Von allen eingeschlossenen Studien wurden die Fallzahlen sowie die Anzahl der HPV 
positiven und negativen Fälle und Kontrollen erfasst. Außerdem wurden allgemeine 
bibliographische Daten sowie Details bezüglich der analysierten Fälle dokumentiert und 
ausgewertet. 
Aus der Gewebebank des Instituts für Pathologie der Universität Regensburg wurden 16 Fälle 
von Plattenepithelkarzinomen der Lunge, welche im Zeitraum von Mai 2017 bis März 2018 in 
der Klinik für Thoraxchirurgie operativ reseziert wurden, herausgesucht. Von 14 Patienten 
war ausreichend Gewebe vorhanden, sodass eine nested PCR nach der Methode von Sotlar et 
al. (1) durchgeführt werden konnte. Von zwei Patienten standen zusätzlich separate bioptische 
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Gewebeproben zur Verfügung, welche beide analysiert und in die Gesamtuntersuchung 
einbezogen wurden. 
Die statistische Auswertung wurde mittels Microsoft Excel (2013) durchgeführt. Die Anzahl 
der HPV positiven und negativen Fälle und Kontrollen wurde aus den selektierten Arbeiten 
extrahiert und nachfolgend die HPV Prävalenzen anhand der einzelnen Patientendaten 
berechnet. Die Berechnung von Mittelwerten und Standardabweichungen erfolgte ebenfalls 
mittels Excel 2013. Die statistische Signifikanz der HPV Prävalenzunterschiede wurde mittels 
Chi-Quadrat-Test berechnet. Ein p-Wert < 0.05 wurde als statistisch signifikant eingestuft.  
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3.3 Ergebnisse 
 
In der durchgeführten Literatursuche im Mai 2018 wurden 3884 Publikationen mit einem 
möglichen Themenbezug gefunden. Nach Deduplikation wurden 2624 Publikationen zum 
weiteren Screening mittels Titel und Abstract in die Literaturverwaltungssoftware Covidence 
eingeschlossen. Es wurden 340 Publikationen in die Volltextanalyse eingeschlossen. Nach 
Anwendung der Ein- und Ausschlusskriterien wurden 73 Veröffentlichungen in diesen 
Systematic Review eingeschlossen. 
Die eingeschlossenen 73 Studien enthalten 8953 Lungenkrebspatienten und 754 
Kontrollpatienten. Die HPV Prävalenz lag bei 13.6 % für alle HPV Arten kombiniert. Die 
HPV 16 Prävalenz war höher als die HPV 18 Prävalenz (6.0 % gegenüber 3.2 %, p<0.01). 
Studien aus Europa, Asien und Amerika erfüllten die Einschlusskriterien. Auf allen 
Kontinenten war die HPV 16 Prävalenz signifikant höher als die HPV 18 Prävalenz (p<0.01). 
Beim Vergleich der einzelnen Kontinente untereinander zeigten sich statisch signifikante 
Unterschiede (p<0.01) mit der geringsten HPV-Prävalenz in Europa (7.5%) gegenüber 16.6% 
in Asien und 11.6% in Amerika. Die HPV Prävalenz in Plattenepithelkarzinomen war höher 
als in Adenokarzinomen (18.6 % gegenüber 9.6 %). Dieser Unterschied war statistisch 
hochsignifikant (p<0.01). Die höchste HPV Prävalenz zeigte sich in Plattenepithelkarzinomen 
bei asiatischen Patienten (29.5 %). 
Um eine zufällige  HPV Detektion einschätzen zu können, wurden die eingeschlossenen Fall-
Kontroll-Studien gesondert analysiert. In den 15 eingeschlossenen Fall-Kontroll-Studien 
wurden 1750 Lungenkrebspatienten und 754 gesunde Kontrollen analysiert. Es wurden nur 
Kontrollen in diese Subgruppenanalyse eingeschlossen, von welchen Lungenbiopsien 
analysiert wurden. Die HPV Prävalenz in den Lungenkrebsproben war statistisch signifikant 
höher als in der Proben der Kontrollgruppe (31.3 % gegenüber 5.4 %, p<0.01). 
Um Unterschiede in der Prävalenz zu minimieren, die durch mögliche Einflussfaktoren 
zustande kommen können, wurden zum einen nur Veröffentlichungen eingeschlossen, welche 
PCR als Nachweismethode nutzen und zum anderen weitere Subgruppenanalysen 
durchgeführt. 
Um einen möglichen Einfluss der Methode, mit welcher das Tumorgewebe behandelt wurde, 
zu untersuchen, wurden die Prävalenzen in den Studien, welche Formalin-fixierte und in 
Paraffin eingebettete Proben verwendeten, mit jenen verglichen, welche frische, gefrorene 
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Proben enthielten. Hierbei ergab sich kein statistisch signifikanter Unterschied der HPV 
Prävalenz (13.4 % gegenüber 13.5 %; p=0.9). 
Da es in den letzten 30 Jahren zu großen Verbesserungen der PCR Methodik gekommen ist, 
wurden die Studien des 21. Jahrhunderts mit den in den 1990er Jahren durchgeführten 
Untersuchungen verglichen. Hier zeigte sich ein statistisch hoch signifikanter Unterschied 
zwischen den beiden Untersuchungszeiträumen (p<0.01) mit einer HPV-Prävalenz von 37.9% 
in den Studien aus den 90er Jahren gegenüber einer HPV-Prävalenz von 8.5 % in den Studien, 
welche im 21. Jahrhundert durchgeführt wurden 
Das Durchschnittsalter der 14 Patienten, welche in Zusammenarbeit mit dem Institut für 
Pathologie der Universität Regensburg untersucht wurden, lag bei 69.6 Jahren. Acht Patienten 
waren männlich und alle Patienten waren aktuelle oder frühere Raucher. (Für einen Patienten 
war keine Raucheranamnese verfügbar.) Bei allen Patienten wurden primäre 
Plattenepithelkarzinome der Lunge diagnostiziert. Die mittels nested-PCR bestimmte HPV 
Prävalenz war 0 %. 
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3.4 Schlussfolgerung 
 
Obwohl in den letzten Jahrzehnten große Fortschritte in der Lungenkrebstherapie gemacht 
wurden, ist Lungenkrebs immer noch mit einer sehr schlechten Prognose vergesellschaftet. 
Die Identifikation von vermeidbaren Risikofaktoren ist daher von besonderer Bedeutung, 
insbesondere bei Patienten ohne Raucheranamnese. 
In vielen Studien konnte HPV DNA in Lungenkrebsgewebe nachgewiesen werden. 
Allerdings konnte bisher kein eindeutiger kausaler Zusammenhang belegt werden. 
Prävalenzunterschiede in Fall-Kontroll Studien deuten jedoch auf einen potentiellen 
Zusammenhang hin. Um dies kausal belegen zu können, sind jedoch weitere Studien 
notwendig, welche ergänzend die Expression der HPV Onkogene und eine mögliche 
Integration von HPV in das Hostgenom untersuchen. 
Geographische Unterschiede der HPV Prävalenz wurden festgestellt mit einer höheren HPV 
Prävalenz in Asien gegenüber Europa und Nordamerika. Allerdings gibt es bisher noch keine 
Erklärungsansätze für diese Beobachtung. 
Der Infektionsweg von HPV im Zusammenhang mit Lungenkrebs ist bisher ungeklärt. Nach 
aktuellem Stand der Forschung verursacht HPV keine Virämie, weshalb eine 
Blutstrominfektion unwahrscheinlich erscheint. Eine direkte Infektion wie beim 
Zervixkarzinom erscheint aber aufgrund der anatomischen Gegebenheiten ebenfalls 
unwahrscheinlich. 
Zusammenfassend werden weitere Studien durchgeführt werden müssen, welche 
insbesondere versuchen, einen kausalen Zusammenhang zwischen HPV-Infektion und 
Lungenkrebs nachzuweisen und einige der obigen Fragen zu beantworten. 
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4. Introduction 
 
4.1 Epidemiology 
 
Lung cancer is estimated to be the leading cause of cancer related mortality worldwide with 
2.1 million new lung cancer cases and 1.8 million predicted deaths worldwide. (1) This 
represents almost one in five cancer deaths worldwide in 2018 (18.4%). 
This is the case not only in smokers. Even in never-smokers lung cancer is the most common 
cause of cancer death worldwide. 
According to the GLOBOCAN 2018 report there will be an estimated 18.1 million new 
cancer cases and 9.6 million cancer deaths in 2018 worldwide. In this statistic all cancer 
subtypes except nonmelanoma skin cancer are included. In both sexes combined lung cancer 
is the cancer type most commonly diagnosed and the leading cause of cancer mortality. Lung 
cancer is the second most frequent type of cancer by incidence and the leading cause of 
cancer mortality in males. In females breast cancer is the most frequent type of cancer and the 
leading cause of mortality followed for incidence by colorectal and lung cancer. Concerning 
cancer mortality lung cancer is the second and colorectal cancer the third most common 
cause. 
The most commonly diagnosed types of cancer underlie geographic variation depending on 
ethnicity, life style factors, virus infections and other still unknown factors. 
Western Europe is one of the regions worldwide where cancer is the number one reason of 
premature death according to the WHO. 
The incidence rate for lung cancer in Western Europe in 2018 is estimated to be 43.3 per 
100.000 in males and 25.7 per 100.000 in females. The lung cancer incidence in males has 
been stable due to a lowering in smoking prevalence. But the lung cancer incidence in females 
is rising in most parts of the world. In some countries, like in the USA for example, the lung 
cancer incidence is now higher in young women then in young men. (2) This is mainly 
attributed to changes in smoking behavior. 
In 2018 a group of Swiss and Canadian scientists estimated the lifetime and 10 year risk of 
developing lung cancer in a Swiss population between 1995 and 2003. (3) During that time 
the estimated lifetime risk decreased in men while it increased in women (7.1% to 6.9% and 
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2.5% to 4.1% respectively). The collected Data also showed that current and former smokers 
have an increased risk of developing lung cancer when compared to never smokers. 
 
4.2 Lung Cancer 
 
Lung cancer was historically divided into two major groups according to morphology: small 
cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC can be further 
divided into adeno-, squamous cell carcinoma, large cell carcinoma and more rare subtypes. 
Over time the distinction between in squamous cell carcinoma and adenocarcinoma has been 
shown to be important as they show differences in response to specific therapies. (4) In the 
last decade lung cancer is increasingly classified by its genetic alterations and oncogenic 
driver mutations. 
Even though imaging techniques play an important role to determine the tumor stadium, in 
contrast to hepatocellular carcinoma (HCC) diagnosis of lung cancer to this day has to be 
verified by histology. 
Approximately 30% of all non-small cell lung cancers are classified as squamous cell 
carcinomas (SCC). (5) SCC is defined as a malignant epithelial tumor expressing squamous 
differentiation in the form of keratinization or bridging. It can be further divided by the degree 
of keratinization into poorly, mildly or highly differentiated SCC. Smokers have a 10-20 fold 
higher risk of SCC of the lung than non-smokers.  
The most commonly altered genes in SCC are: FGR1 (fibroblast growth factor receptor 1), 
PIK3CA (phosphoinositide-3-kinase catalytic subunit alpha isoform), DDR2 (discoidin 
domain receptor 2), MET, SOX2 (SRY related HMG box gene 2), PTEN (phosphatase and 
tensin homolog) and CDKN2A (TP53 and cyclin-dependent kinase inhibitor 2A). Some of 
these have therapeutic consequences already while others are still subject of ongoing research. 
Adenocarcinomas (AC) represent approximately 50% of all NSCLC and approximately 38% 
of all lung cancers in the Western world. (6) Distribution of histological subtypes does 
underlie some geographic differences. Anatomically they are more often located in the 
periphery of the lung. Usually diagnosis is achieved by light microscopy where glandular 
morphology can be seen. This morphology can be further divided into acinar, leptic, papillary 
or solid with mucin patterns. Further evaluation of AC is done by immunohistochemistry 
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using adenocarcinoma marker. Apart from that adenocarcinomas are tested for oncogenic 
mutations which allow for targeted therapies.  
The most commonly tested for altered genes in adenocarcinomas are:  
- EGFR (epidermal growth factor receptor) 
- EML4-ALK (echinoderm microtubule associated protein-like protein 4 fused with 
anaplastic lymphoma kinase) 
- KRAS (Kirsten rat sarcoma viral oncogene homolog) 
- MET (mesenchymal-epithelial transition factor) 
- ROS1 (c-ros oncogene 1) 
- RET (rearranged during transfection) 
- BRAF (v-Raf murine sarcoma viral oncogene homolog B1) 
- TP53 (tumor suppressor protein 53) 
Some of these gene alterations are aims for targeted therapies (e.g. EGFR = Gefitinib, 
Erlotinib; ALK = crizotinib, alectinib) and are therefore routinely tested for in newly 
diagnosed lung cancers. 
The symptoms of lung cancer are unspecific such as coughing or hemoptysis. In many cases 
B-symptomatic is the first sign of a malignant disease which usually only occurs in a more 
advanced tumor stage. This and the lack of a reliable screening method or tumor marker is the 
reason why lung cancer is most often diagnosed in an advanced tumor stage. 
In a British study using the data from the National Cancer Registration the results showed that 
with an increased tumor stage at diagnosis the one year survival decreased. (7) While in some 
tumor entities a major decrease in survival rates is associated with stage 4 cancer (e.g. breast, 
colorectal cancer) in lung cancer a decrease in survival rates can be seen in every tumor stage. 
To this day lung cancer prognosis can best be determined according to the TNM stage at 
primary diagnosis. (6) According to the International Association for the Staging of Lung 
Cancer (IASLC) the current 5 year survival rate based on TNM classification decreased from 
73% in stage IA cancer to 13% in stage IV. 
Outcome in patients with SCLC is even worse with a 2 year survival rate of only 4.6%. (8) 
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4.3 Etiology 
 
Tobacco smoking is still the main cause of lung cancer worldwide. (9) Usually the amount of 
smoking patients have done in their life is related to the amount of tobacco consumed over 
time (“pack-years”). (10) Even though there are lung cancer cases in never-smokers there is a 
strong correlation between smoking and lung cancer incidence, most prevalent in small cell 
lung cancer and squamous cell carcinoma. On the other hand adenocarcinoma is the most 
common lung cancer subtype in never-smokers. (4) 
Apart from smoking different risk factors have been suggested especially in never-smokers 
such as environmental tobacco smoke, air pollution, cooking oil fumes. (11) Different 
pulmonary diseases have been identified that are associated with a higher risk for lung cancer 
e.g. former infection with tuberculosis, COPD, emphysema. (12) Up to this point the causal 
association between these diseases and the development of lung cancer has not been fully 
established. On the other hand there are risk factors specific to certain occupations (e.g. coal 
miners) or certain geographic regions (e.g. areas with domestic radon exposure). 
A growing number of lung cancer incidence takes place in never-smokers. This group makes 
up between 15 and 25% of the lung cancer patients and accounts for up to 300.000 deaths 
every year. (13) If lung cancer in never smokers would be accounted for as an original entity 
among cancer types it would still be the seventh leading cause of mortality among solid 
tumors. Lung cancer in never-smokers is more frequent in women and there are distinct 
oncogenic mutational patterns. ALK and EGFR activating mutations are frequent and with 
consequences both for therapy and prognosis. Today’s data on chemotherapy response in 
smokers as compared to never-smokers is not conclusive but an area of ongoing research. 
That is why some scientists suggest to treat lung cancer in never-smokers as an independent 
tumor entity. 
In recent years cancer prevention has been a topic of increased interest in scientific research. 
It is undisputable that smoking cessation is the most important factor in prevention of lung 
cancer development. Smoking cessation reduces the risk for all subtypes of lung cancer, 
especially for SCC and SCLC. 
To this day no reliable tumor marker for lung cancer screening has been established. In 2011 
a large multi-center study on lung cancer screening in high risk patients was conducted by 
The National Lung Screening Trial Research Team in the United States. (14) From 2002 
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through 2004 approximately 53.000 patients in 33 US medical centers were included and 
randomly assigned into a group that was screened with low dose CT-scan or conventional 
chest X-ray. Results have shown that low dose CT scan was able to reduce lung cancer 
mortality in a high risk population. No lung cancer screening programs for high risk patients 
or for the general public have yet been established. 
 
 
4.4 Human Papillomavirus 
 
Since the first identification of human papillomavirus more than 200 different subtypes have 
been identified. They are classified into high-risk HPV types (16,18,31,33,39,45,51,52,58) 
and low-risk HPV types (6,11,42,43,44). (15) In some other publications a differentiation 
between high-, intermediate- and low-risk HPV types is made. 
Human papillomaviruses are small non-enveloped viruses which belong to the 
Papillomaviridae family. They are between 50 and 60 nanometer in diameter and contain one 
circular, double-stranded DNA genome consisting of approximately 7000 to 8000 bp. The 
genome is divided into three regions: the long control region (LCR), the early region (E) and 
the late region (L). (16)  
The long control region controls viral gene expression and replication while the late region 
encodes structural proteins. The early region encodes genes needed for viral gene expression, 
replication and survival. The names of the different regions refer to the phase in the viral life 
cycle in which they are expressed. 
Those main regions can be further divided by the function of their gene products. According 
to today’s research the early region encodes for six different proteins. Of those E5, E6 and E7 
are the three oncogenes encoded by the virus. E5 is involved in disturbing growth-factor 
signaling pathways and avoiding the host immune system. E6 and E7 work synergistically to 
provide an environment that allows the virus to replicate. E6 of high-risk HPV-types also 
targets the tumor-suppressor protein p53 and inactivates it. E7 as the third encoded 
oncoprotein targets cell-cycle regulating proteins such as retinoblastoma protein (Rb). 
As for the other early proteins: E1 possesses DNA helicase activity and is thereby the only 
enzyme encoded by a HPV virus, E2 controls the expression of the other proteins and it 
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recruits E1 to the viral origin. It thereby increases viral DNA replication. As a third function it 
plays a critical role in transferring the viral genome during division of the host cells. The 
function of E4 is still unknown. (17) 
There are two late genes (L1 and L2) and one long control region (LCR) which regulate the 
expression of the early genes. L1 and L2 are the major and minor components of the viral 
capsid. The L1 region can form virus-like particles (VLPs) which are the basis for 
prophylactic vaccination. 
Many different regions of the HPV genome can be detected by PCR: some, for example the 
L1 regions, can be used as consensus primers to detect many different types of HPV and some 
like the E6 and E7 as type specific primers (e.g. E6 HPV16 and E7 HPV18). 
HPVs are epitheliotropic and their life cycle takes place in squamous epithelia. According to 
current knowledge HPV enters through microtrauma in the epithelia and reaches the basal cell 
which is believed to be the target cell for HPC infection. The infection method of HPV is not 
yet fully understood. After initial infection there seems to be an unproductive state in which 
only the early viral oncogenes are expressed. One of the specific features of HPV infection is 
its ability to persist over years. To achieve this the viral genome has to be preserved over 
multiple cell division. The method by which this is achieved is still unknown. When one of 
the daughter cells starts to differentiate the virus starts its productive stage. The virus redirects 
the host cells DNA replicative system and amplification and expression of late viral genes 
starts. Those are necessary to subsequently produce progeny virus and release them. 
Almost all studies on HPV are done on cervical cancer cells. It has not yet been established 
whether all of the before mentioned stages and means of infection are also valid in other 
infection sites. 
The transmission route of HPV into lung tissue has not been explained. One of the possible 
infection routes is oral sexual activity as a possible pathway to lung cancer cells. Another 
possible route that has been discussed is hematogenous. Neither of that could be proven by 
now. (18)  
Some studies have tried to detect HPV DNA in blood cells. But even though HPV 16/18 
prevalence has been shown to exist in some studies (19), these results are still very 
controversial because to this day it is believed that HPV infection does not cause viremia. 
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4.5 HPV and Cervical Cancer 
 
In 1979 Kari J. Syrjänen first published a case report describing histological changes in 
bronchial epithelium resembling a squamous cell carcinoma of the lung similar to changes of 
condylomatous nature in the genital tract. (20) Even though an association of HPV with 
carcinogenesis was not established at that time it was proposed to observe such lesions closely 
until proven otherwise. 
The Nobel Prize in Physiology or Medicine 2008 was awarded to Harald zur Hausen for 
establishing the connection between HPV infection and cervical cancer. He first drew 
attention to a possible association between HPV infection and carcinogenesis in 1976. (21)  
In the 1960s there were first reports about double stranded DNA of the human papillomavirus 
which in the 1970s was further distinguished to be different types of HPV. (16) But it wasn’t 
until 1974 when the human wart virus was isolated from plantar warts by zur Hausen et al. 
and used for hybridization of cutaneous, genital warts and cervical cancer. (HPV was still 
referred to as Human Wart Virus then).While high positive rates were found in cutaneous 
warts, no positive signal was seen in cervical cancer specimens. (22) The authors concluded 
that more research had to be done on the possible existence of different types of HPV virus. 
This hypothesis was later proven in different studies. (23) 
The first experiments to establish a relationship between HPV and cervical cancer were 
initiated in 1972 by zur Hausen in Heidelberg. (24) In 1976 Meisels and Fortin first suggested 
that there might be an association between koilocytotic cells that were found in cervical 
cancer and HPV infection. (25) 
In 1982 the first three publications on HPV DNA sequences in human tumors were published. 
They all referred to cervical cancer. 
In the following years research about the association of HPV and cervical cancer increased 
proving for example the interaction of E6 with p53 and its resulting protein degradation. (26) 
Today the carcinogenetic potential of HPV is well established and it is known that more than 
95% of cervical cancer biopsies contain high-risk HPV subtypes. 
Three different types of HPV vaccination are currently available (e.g. Gardasil, Gardasil 9, 
Cervarix). (27) Since 2015 the WHO recommends a two dose program. And vaccination with 
Gardasil has been proven to be effective to reduce the incidence of HPV 16/18 infection. It 
 - 17 - 
 
has not yet been fully established whether vaccination is also effective in cervical 
intraepithelial neoplasia (CIN) or adenocarcinoma in situ. 
 
4.6 HPV and other Organ Sites 
 
Since the oncogenic potential of HPV has been established there has been a lot of research on 
a possible association of HPV with cancers of other organ sites. 
Shortly after HPV DNA was detected in cervical cancer some of the same as well as new 
HPV subtypes were detected in other anogenital cancers. But since many of the risk factors of 
cervical cancer are the same as for other anogenital cancers a causal relationship between 
HPV infection and those kinds of cancer is still subject to ongoing research. (28) Even though 
HPV DNA has been detected in vaginal, penil and anal cancer. 
Recurrent respiratory papillomatosis is a rare disease where benign tumors (papilloma) form a 
long the aerodigestive tract. Although these papillomas usually cause a mechanical problem 
(e.g. obstruction of the airways), some cases of transformation of these papillomas into 
squamous cell carcinomas have been described. (29) Today it is well established that 
recurrent respiratory papillomatosis is associated with HPV infection. 
So one of the organ sites that have been examined early are tumors of the upper aerodigestive 
tract and head and neck cancer. (30) 
In recent years research was done on most other organ sites. There are still many questions 
concerning HPV infection: e.g. how long and where do transient infections take place, does 
HPV cause viremia, does HPV present an individual risk factor in other organ sites like it 
does in cervical cancer or does it present as an co-carcinogen and does every high-risk HPV 
infection impose a risk of developing cancer in every organ site.  
HPV DNA has not only been detected in neoplastic tissue, but also in normal tissue in several 
organ sites. Its meaning has yet to be determined. 
Since the first suggestion of a possible association between HPV and lung cancer numerous 
studies have been executed all over the world. Those include not only different types of 
detection but also different sampling methods. In this meta-analysis and the included analyzed 
tumor tissue we took a closer look at HPV detection by PCR in bronchoscopic biopsy 
specimens or resected lung tissue in primary squamous cell carcinoma of the lung. 
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5. Materials and Methods 
 
5.1. Meta-analysis 
 
The intention behind conduction of this systematic review was to get an idea of the 
prevalence of HPV infection in lung cancer both internationally and on the different 
continents as basis for further research and to detect the possibility of an association in our 
own patient collective. 
Reporting of this meta-analysis is done according to the recommendation of Stroup et.al (31) 
for reporting observational studies published in 2000. They held a workshop 1997 in Atlanta 
with twenty-seven participants who were selected by a committee based on their clinical, 
statistical and other expertise. A systematic review of the published literature on reporting 
meta-analysis of observational studies was conducted. Based on the workshop results a 
checklist of recommendations on what to report was developed. These are referred to as 
“MOOSE” (Meta-analysis of Observational Studies in Epidemiology)-criteria. 
 
5.1.1 Literature Research 
 
Before starting the literature research we registered the concept for our meta-analysis on the 
international prospective register of systematic reviews (PROSPERO) in March 2018. At that 
point of time no other systematic reviews on the association of HPV infection and lung cancer 
were registered. 
In cooperation with Dr. Helge Knüttel a librarian at the medical library of the University 
Clinic Regensburg we searched the digital databases EMBASE (via Ovid, 1974–present), 
MEDLINE (via Ovid, 1946–present), Cochrane Library (Cochrane Database of Systematic 
Reviews, Database of Abstracts of Reviews of Effect, Cochrane Central Register of 
Controlled Trials, Health Technology Assessment Database, NHS Economic Evaluation 
Database; from inception to present) and Science Citation Index Expanded (Web of Science, 
1965–present) as well as the search engine Google Scholar (no date limit). 
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Using the default sort order by relevance only the first 200 records from Google Scholar were 
assessed. Records from Google Scholar were downloaded with Anne-Wil Harzing’s “Publish 
or Perish” program (https://harzing.com/resources/publish-or-perish). 
In addition to the bibliographic databases we searched the following registers of clinical trials 
for completed studies: WHO's International Clinical Trials Registry Platform, 
ClinicalTrials.gov, EU Clinical Trials Register and the German Clinical Trials Register. 
We employed highly sensitive search strategies in order to identify all possibly relevant 
studies. We searched for the concepts “lung cancer” AND “HPV”. Controlled terms from the 
databases’ thesauri and a broad range of synonyms were used. Within each concept search 
terms were combined using the Boolean operator OR. No limits such as for study type, 
publication type, publication date or language were applied. We adjusted the search strategy 
according to the databases/search engines. 
A draft search strategy for EMBASE (Ovid syntax) was published and is available from:  
http://doi.org/10.5283/epub.36830. 
We screened the reference lists of included studies and of relevant systematic reviews for 
additional studies. 
Records from searching were uploaded to a reference management software for deduplication. 
Screening and eligibility assessment was done using the COVIDENCE online program for 
managing systematic reviews. 
 
5.1.2 Acquisition of Publications 
 
The full texts of the publications identified by the literature research were found via internet 
research or if the full text was not available online, by borrowing paper copies from our own 
library or by contacting other libraries through different services offered by our medical 
library (“Fernleihe”, “Subito”). 
The full texts were obtained in the original language. If that was neither German nor English a 
translation was made using an online translation program and checked with a college or 
translator fluent in that particular language. 
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5.1.3 Data Selection 
 
After deduplication the titles and abstracts of the remaining publications were analyzed by 
two independent reviewers (Dr. Franziska Koll, Julia Karnosky) for relevance and matching 
inclusion criteria. If there was no concordance between the two reviewers the final decision 
was made by an independent third reviewer (Prof. Christian Schulz). Those publications 
where no abstract was available were included into the full text review as well. 
All studies that were recognized as possibly eligible for inclusion were analyzed using 
EndNote Citation Software (Version X9). 
For all the included full texts the same analysis system with the same reviewers was used.  
Analysis of the publications was done according to the following inclusion and exclusion 
criteria: 
 
5.1.3.1 Inclusion Criteria 
 
All studies reporting HPV prevalence in primary lung cancer cases in adults were included. 
Case reports were excluded. As detection method only PCR from fresh frozen and/or paraffin-
embedded tissue were included. HPV detection in blood samples or any other means of 
detection was excluded. All types of tissue sampling method were included. HPV detection in 
archival tumor tissue was included as well. 
No exclusion was done depending on whether HPV low-risk or high-risk were analyzed. 
Only studies that provide data specific to HPV prevalence in lung cancer tissue were 
included.  
No exclusions were made based on language. We included journal articles as well as abstracts 
and conference reports if they met the inclusion criteria. If an abstract and a journal article on 
the same patient population was available the journal article was included. Journal articles 
that reported about not only cases of HPV detection in primary lung cancer but e.g. in head 
and neck cancer as well, were included but only the data of the primary lung cancer group 
were extracted. 
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5.1.3.2 Exclusion Criteria 
 
Exclusion Criteria were as following: 
- Case Reports 
- Reviews 
- HPV detection in minors 
- Any data on HPV prevalence that was done by a detection method other than PCR 
- HPV detection in blood samples or any other biomaterial then tumor tissue 
- HPV infection in non-primary lung cancer or metastatic disease of a different primary 
origin 
- Publications for which neither abstract nor full text were available online or by 
borrowing a paper copy through a library 
The excluded full text publications were documented stating the reason for exclusion. 
 
5.1.4 Data Extraction 
 
For all included studies title, first author, year of publication, country of research, journal in 
which the study was published and language of publication were collected. Additionally the 
study size, the detection method for HPV, the tissue sampling and processing method and the 
types of HPV detected were collected to be able to compare the overall prevalence of HPV 
infection in lung cancer to our own experiments. Not only the calculated HPV prevalence in 
the included studies but also the case numbers as well as the number of cases detected to be 
positive and negative were collected. 
Data for a subgroup analysis for Squamous Cell Carcinoma and HPV types 16 and 18 were 
gathered as well. 
In order to evaluate other possible factors influencing the results a subgroup analysis was 
done on basis of the used tissue processing method. 
To exclude that any detected difference is influenced by improvement in PCR technology the 
studies were stratified by the time in which they were done and analyzed separately in another 
subgroup analysis. 
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5.2 Experimental Part 
 
5.2.1 Biopsy Material 
 
All the included materials were obtained from the tissue bank at the department of pathology 
at the University of Regensburg. Initially a list of 16 patients with primary SCC of the lung 
diagnosed in 2017 or 2018 was created. After obtaining the biopsy specimens it was 
determined that enough tissue for PCR was still available for 14 patients. In addition two 
separate biopsy specimens were available for two patients. Both were included in the final 
analysis. From all the included patients paraffin-embedded tissue from resected lung cancer 
was available. All of them were operated on by the Department of Thoracic Surgery at the 
University Clinic Regensburg between May 2017 and March 2018. 
 
5.2.2 HPV Detection 
 
HPV detection was done according to the method reported by Sotlar et al. in 2004. (32) They 
evaluated a nested multiplex PCR assay. It incorporates consensus primers and type-specific 
primers. The viral E6/E7 oncogenes are used as primer targets. In the first round of 
amplification a broad spectrum of HPV subtypes is analyzed. 18 different HPV subtypes 
including all known high-risk HPV types are included. They were combined with type-
specific primers used for nested PCR in following rounds of amplification. This novel PCR 
assay was initially tested on cervical scrapes. In their study the detected sensitivity of this new 
multiplex PCR was similar to the sensitivity of the nested PCRs done with consensus primers 
MY09/MY11 and GP5+/GP6+ combined. The sensitivity was higher than in a conventional 
PCR with either of the two. The advantage of this way of HPV detection is that it allows for 
exact HPV typing and detection of multiple HPV types at once. 
All experimental analyses were carried out in cooperation with the Department of Pathology 
of the University Hospital Regensburg.The in this institute already established methodology 
of HPV-analytics was employed to the subject of this study. The evaluation of the multiplex-
PCR-data was performed under the supervision and in cooperation with Prof. Dr. Wolfgang 
Dietmaier, chief of molecular pathological diagnostics in the Department of Pathology. 
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5.3 Statistical Analysis 
 
All publications that matched the inclusion criteria were added to an Excel chart. Data was 
analyzed using Microsoft Excel (2013). The total number of cases as well as the number of 
positive and negative HPV detection were collected and the overall HPV prevalence was 
calculated. All tests for statistical significance were done using the Chi-squared-test. A p-
value < 0.5 was determined to be statistically significant. Afterwards all the calculation were 
repeated using SPSS Version 22. 
Other information e.g. on smoking behavior, gender etc. was collected from the individual 
publication. Mean value of age as well as standard deviation were calculated by means of 
Excel 2013. 
If the information was not available in all of the included studies its information was collected 
for the studies that provide it and the number of studies which do so is acknowledged. 
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6. Results 
 
6.1 Meta-analysis 
 
6.1.1 Databank Research 
 
An overview of all analyzed studies is documented in the PRISMA flowchart (Appendix 
Figure 3: Prisma flowchart). 
 
6.1.2 General Literature Research 
 
In the literature research done in May 2018 3884 publications with a possible connection to 
the research question were found in the following databases respectively:  
• Medline (n=705),  
• Embase (n=1376),  
• Cochrane (n=12),  
• Science Citation Index Expanded (n=1508),  
• Google Scholar (n=200),  
• WHO's International Clinical Trials Registry Platform (n=5),  
• ClinicalTrials.gov (n=28) 
• EU Clinical Trials Register (n=10).  
After deduplication the remaining 2624 publications were imported into Covidence 
(management software for systematic reviews run by the Cochrane library). 
They were evaluated by both reviewers on relevance for the research question. 2268 of the 
screened titles and abstracts did not relate to the current research and were excluded. For 16 
publications no abstract was available, so it was not possible to evaluate whether the 
publication might be relevant. The decision was made to include these 16 publications into 
the full text review as well. In summary 340 publications were entered into the full text 
review. 
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The full text version of three of these publications was not available neither online nor by 
borrowing the paper version from a library (33-35). 
The remaining 337 full text versions were screened by both investigators. After applying the 
inclusion and exclusion criteria 73 publications were included in this systematic review. 
Reason for exclusion Number of publications 
No PCR 67 
Overview articles without new data 28 
Duplicates 22 
Systematic Reviews or Meta-analysis 26 
No data on HPV prevalence 28 
No biopsies 25 
Abstract of included full text 11 
Case report 9 
Comments on other articles 9 
Same patient data in different publication 7 
Biopsies from organs other than the lung 6 
Studies on special patient groups 5 
Correction of another article 5 
Non primary lung cancers 6 
Unfinished studies 2 
No details on HPV detection method 2 
Recurrent respiratory papillomatosis 2 
No data on sampling method 2 
English version included 2 
Total number of excluded full text studies 264 
 
Table 1: Excluded full text studies 
 
The most common reason for exclusion was that no PCR was done to detect HPV. This was 
the case in 67 publications. In two studies the HPV detection method was not detailed. While 
manually screening the included title and abstracts 22 more duplicates were found and 
excluded. Nine publications were case reports. There were five corrections and nine 
comments on publications that were screened. Since none of the corrections changed the 
content of the publications they were excluded. 
There were 26 systematic reviews and meta-analysis which were analyzed separately for 
additional studies but were not included. An additional 28 overview articles were excluded 
because they did not specifically provide data on HPV prevalence in lung cancer. 
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In 25 studies no lung biopsies were analyzed but HPV detection was done in other materials 
such as blood samples or cell lines. Six studies analyzed HPV prevalence in cancers other 
than lung cancer or on metastasis. 
While 28 studies did give detailed information on different aspects of lung cancer no data on 
HPV prevalence was included. 
We included study registers into our general literature research. After screening the titles and 
abstracts of the registered studies two were included into the full text review. The aspired date 
of conclusion for these two studies is set after this systematic review is finished. 
The same patients were analyzed in two separate publications in seven cases. The newer or 
the one providing more detail was included if they fit the inclusion criteria. Four studies were 
published twice with the same information but in different languages. In these cases the 
English version was included. 
In 11 cases an abstract was found published in a different journal than the full text. In these 
cases only the full text was included since the abstract did not provide additional information. 
Five studies reported on HPV prevalence in lung cancer in special patient groups e.g. patients 
after lung transplantation, immunocompromised patients and butchers. Those were excluded 
because the spectrum of infections known to occur in such patient group differ from those in 
other patients. For the same reason two publications on HPV prevalence in patients with 
recurrent respiratory papillomatosis were excluded. 
 
6.1.3 Overview of the Literature 
 
After application of inclusion and exclusion criteria 73 publication were eligible for inclusion. 
A list of all included studies is recorded in Table 19: List of publications. 
15 of the publications were case-control studies in which lung tissue was used as a control. In 
the case that studies did use other tumors as controls (e.g. cervical cancer tissue) or the control 
was not done on tissue but for example blood samples, only the data of the analyzed lung 
tumor tissue were included and the study was not counted as a case-control study. 
The studies were stratified according to the geographical region in which the patients lived. 
No studies from Africa or Australia were found. There were 35 studies on patients from Asia, 
23 studies on European patients and 15 studies carried out on the American continent. 
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The countries most represented were: Japan (n=11), China (n=10), USA (n=9) and Italy 
(n=5). Only three studies from Germany met the inclusion criteria. Six studies were done in 
multiple countries with the information summarized in one publication. 
We did not exclude publications because of the language in which they were published. Most 
of the publications were written in English (n=68). The other publications were published in 
Chinese (n=3), French (n=1) and German (n=1). If a paper was published in more than one 
language but with the same content the more recent edition was included. 
In order to get information on as many cases as possible not only journal articles but every 
type of available publication was included. Of the 73 included publications 62 were journal 
articles. Of the remaining publications 6 were abstracts, 3 were poster presentations and 2 
were meeting abstracts. 
The research included in this systematic review was published in more than 20 journals 
worldwide. The most common being: Lung Cancer (n=5), British Journal of Cancer (n=4), 
Oncology Reports (n=4) and Oncology Letters (n=4). 
Of all the included studies 26 were performed in the 21st century. Of the remaining studies six 
were done in the 1990s. In 29 cases no data on the time of research was available. The time of 
research in the remaining 12 studies spanned both the 1990s and 21st century. 
 
 
6.1.4 Patients Characteristics 
 
A total number of 8953 lung cancer patients was included into this systematic review. 
Of all the included studies 25 provided data on the patients age. The average age of the 
included patients was 62.2 years (SD: 4.9 years). 
Information on patients’ gender was available in 48 out of the 73 included studies. Those 
studies included 5957 patient. Of them 3756 were male and 2201 were female, 63.1 % and 
36.9 % respectively. 
Smoking behavior was detailed in 31 of the studies (42.5 %). There were 3409 current or 
former smokers, 1767 never smokers and in 3777 cases no information on smoking status was 
available. The rate of smokers was 38.1 %. If only the rate of smokers in the studies that 
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provide such information is calculated the rate of smokers is 62.7 %. This rate has to be seen 
very critical since both studies only including non-smokers as well as only smokers were 
included. It also has to be taken into consideration that there is no generally accepted rule to 
when a patient is considered to be a smoker. Definitions vary largely. 
Only the information on primary SCC and primary AC of the lung was collected. There were 
2629 cases of SCC and 2669 cases of AC. In the remaining cases it was neither one of them 
or the histological subtype was not detailed. In total 29.4 % of the included cases were 
squamous cell carcinomas and 29.8 % were adenocarcinomas. 
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6.1.5 Continents 
 
6.1.5.1 Europe 
 
 
Reference Country No. 
of 
cases 
Year HPV 
prevalence 
in % 
Specimen 
type used 
Histologíc 
subtypes tested 
HPV 
types 
detected 
 
Anantharaman 
et al. (36) 
multiple 
European 
countries 
290 2014 9.7 FFPE, 
fresh 
frozen 
SCC/AC/others 11,16, 
51,58 
 
Argyri et al. 
(37) 
Greece 67 2017 3.0  SCC/AC/others 16,53 
 
Carpagnano et 
al. (38) 
Italy 89 2011 16.4 FFPE SCC/AC/others 16,30, 
31,39 
 
Ciotti et al. 
(39) 
Italy 38 2006 8.0 FFPE, 
fresh 
SCC/AC/others 16,18 
 
Coissard et al. 
(40) 
France 218 2005 1.8 fresh 
frozen 
SCC/AC/others 16 
 
Eberlein-
Gonska et al. 
(41) 
Germany 55 1992 5.5 fresh SCC/AC/others 16 
 
Galvan et al. 
(42) 
Italy, 
United 
Kingdom 
100 2012 0 fresh 
frozen 
SCC/AC/others none 
 
Gatta et al. 
(43) 
Italy 50 2012 4.0 FFPE SCC  
 
Guliani et al. 
(44) 
Italy 78 2007 12.8 fresh 
frozen 
SCC/AC/others 16,18, 
31,53 
 
Hennig et al. 
(45) 
Norway 22 1999 13.6 FFPE SCC/AC/others 6 
 
Miasko et al. 
(46) 
Poland 94 2004 12.7  SCC/AC/others  
 
Miasko et al. 
(47) 
Poland 40 2001 10.0 FFPE SCC/AC/others  
 
Papadopoulou 
et al. (48) 
Greece 52 1998 40.0 fresh 
frozen, 
FFPE 
SCC 6,11, 
16,18 
 
Podsiadlo et 
al. (49) 
Poland 33 2012 3.0 fresh NSCLC/SCLC 120 
 
Sagerup et al. 
(50) 
Norway 334 2014 3.9 fresh 
frozen 
SCC/AC/others 11,16, 
33,66 
  
Sarchianaki et 
al. (51) 
Greece 100 2014 19.0 FFPE SCC/AC/others 6,11,16, 
18,31, 
33,59 
 
Shamanin et 
al. (52) 
Germany 85 1994 0 fresh 
frozen 
SCC/AC/others none 
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Spandidos et 
al. (53) 
Greece 99 1996 15.0 FFPE SCC/AC/others 11,16, 
18,33 
 
Syrjanen et al. 
(54) 
Finland 77 2012 5.2 FFPE, 
archival 
tissue 
SCC/AC/others 6,16 
 
Van Boerdonk 
et al. (55) 
Netherlands 211 2013 0 FFPE, 
archival 
tissue 
SCC/AC/others none 
 
Thomas et al 
(56) 
France 31 1995 16.0 fresh 
frozen 
SCC/AC/others 6, 11 
 
Welt et al (57) Germany 38 1997 0 FFPE SCC/SCLC none 
 
Zafer et al (58) Turkey 40 2004 5.0 fresh 
frozen 
SCC/AC/others 18 
Total   2226      
 
Table 2: European studies 
 
From Europe 23 studies were included containing 2226 patients. The most common countries 
of origin were Italy (n=4) and Greece (n=4), followed by Germany (n=3) and Poland (n=3). 
HPV prevalence was tested in multiple countries and reported in one publication in two 
studies (36, 42). 
21 publications were in English, one in French (56) and one in German (41). 
Of all the European studies 19 publications were journal articles, two poster presentations, 
one meeting abstract and one was an abstract. 
All of the included studies from Europe incorporated NSCLC tumor biopsies. 
Two of the included studies only contained SCC samples.(43, 48) There were no studies only 
analyzing adenocarcinomas found in Europe. 
The processing method of the analyzed tissue was not detailed in two of the included studies 
(37, 46).  
Of all the included studies 13 used formalin-fixed paraffin-embedded tissue (56.5 %), nine 
studies used fresh frozen tissue, two studies used fresh tumor specimens (41, 49) and one 
study also included archival tissue(55). Four studies analyzed tissue that was processed by 
more than one of the methods. 
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Information on the used primers was available in seven studies (30.4 %). The primer used 
most often in the European subgroup was the consensus primer MY09/MY11 (n=5). 
Four of the included studies were case-control studies (38, 41, 42, 51). 
The total number of cases included in these studies was 351, the number of controls was 222. 
The number of HPV positive cases and controls was 37 and one case respectively. The overall 
HPV prevalence was calculated to be 10.5 % in the lung cancer cases compared to 0.45 % in 
the control cases from benign lung disease. 
Only in nine studies information on the patients’ age was provided. The average age was 64.7 
years with a standard deviation of 2.3 years. 
Information on the patients’ gender was available in 13 of the included studies. 66.5 % of the 
patients were male and 33.5 % were female (935/472 cases). 
Smoking behavior was detailed in 11 studies. 44.3 % were current or former smoker, 4.2 % 
were never smokers and in 51.5 % the smoking behavior was unknown. 
All but five studies contained information on the tissue sampling method. It was resected lung 
tissue in nine studies and bronchoscopic biopsy in three. In six studies both surgically 
resected lung tissue and bronchoscopic biopsies were analyzed. 
The total number of cases included from Europe was 2226. The maximum number of cases in 
one of the studies was 334, the minimal 22. On average there were 96.8 patients per study. 
The most prevalent HPV subtype detected was HPV 16 (n=21), followed by HPV 18 (n=7). 
No data on the detected HPV subtype were available in three studies (43, 46, 47). 
Of the included 2226 cases 168 were detected to be HPV positive by PCR. The HPV 
prevalence in the European subgroup was 7.5 %. The highest detected HPV prevalence in one 
of the European studies was 40 % (48). No HPV DNA was detected in four of the studies (42, 
52, 55, 57). 
Data on HPV 16 prevalence was included in 15 of the European studies. In total 1556 cases 
were tested of which 61 were found to be HPV 16 positive (3.9 %). Information on HPV 18 
prevalence was available in 13 studies. HPV 18 prevalence was detected to be 0.8 %, meaning 
11 out of the 1436 therefore analyzed cases. 
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 Positive Negative Total 
HPV 16 61 1495 1556 
HPV 18 11 1425 1436 
 72 2920 2992 
 
Table 3: HPV 16 and 18 prevalence in Europe compared 
 
The difference between the detected HPV prevalence for HPV 16 and HPV 18 in the included 
European studies was statistically highly significant (p<0.01). 
The number of included studies from Europe that contained information on HPV prevalence 
in squamous cell carcinoma of the lung was 19. Of the included 798 cases 43 were HPV 
positive (5.4 %). Four studies did not detect HPV DNA in SCC (42, 52, 55, 57). 
Ten studies incorporate information on HPV 16 prevalence in SCC; it was calculated to be 2.8 
%. Of the studies on SCC nine provided data on HPV 18 prevalence. Only three of the 
analyzed 408 lung cancer cases were detected to be HPV 18 positive (0.7 %). 
Samples of adenocarcinomas of European patients were analyzed in 17 studies. In total 763 
cases were examined. 52 cases were HPV positive (6.8 %). The prevalence for HPV 16 (n=9) 
and HPV 18 (n=8) in adenocarcinomas was 2.9 %. In eight studies AC samples were analyzed 
for HPV 18 DNA. None of the analyzed 365 cases were tested to be positive for HPV 18 
DNA. 
 
 HPV 
positive 
HPV 
negative 
Total 
SCC 43 755 798 
AC 52 711 763 
 
95 1466 1561 
 
Table 4:HPV prevalence in SCC and AC in Europe compared 
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There was no statistically significant difference between the HPV prevalence in SCC and AC 
analyzed in the included studies from Europe (p=0.24). 
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6.1.5.2 Asia 
 
 Reference Country 
No. 
of 
cases 
Year 
HPV 
prevalence 
in % 
Specimen 
type used 
Histologic 
subtypes tested  
HPV types 
detected 
 
Aguayo et al. 
(59) 
Pakistan, 
China 
60 2010 13.0 FFPE SCC/AC/others 16 
 
Baba et al. 
(60) 
Japan 57 2010 19.3 FFPE SCC/AC 6,16, 
18,33 
 
Cheng et al. 
(61) 
Taiwan 141 2004 38.3  SCC/AC 6,11 
 
Cheng et al. 
(62) 
Taiwan 141 2001 54.6 FFPE, 
fresh 
frozen 
SCC/AC 16,18 
 
Fan et al. (63) China 262 2015 8.4 FFPE SCC/AC 16,18, 
31,58 
 
Goto et al. 
(64) 
Japan/ 
Singapore/ 
China/ 
Korea 
304 2011 7.9 FFPE SCC/AC 6,11, 
16,18 
 
Halimi et al. 
(65) 
Iran 30 2011 10.0 FFPE SCC  
 
Hartley et al. 
(66) 
Lebanon 20 2015 0 FFPE SCLC none 
 
Hirayasu et 
al. (67) 
Japan 73 1996 60.3 FFPE SCC 6,16,18 
 
Hiroshima et 
al. (68) 
Japan 22 1999 4.5 FFPE AC 16 
 
Ilahi et al. 
(69) 
Pakistan 9 2016 11.1 FFPE SCC/AC/others 16 
 
Isa et al. (70) Japan 96 2015 1.0 FFPE SCC/AC/others 6 
 
Ito et al. (71) Japan 901 2014 0.9  SCC/AC/others  
 
Iwakawa et 
al. (72) 
Japan 297 2010 0 fresh 
frozen 
AC none 
 
Jafari et al. 
(73) 
Iran 50 2013 18.0 FFPE SCC/AC/others 6,18 
 
Jain et al. (74) India 40 2005 5.0 fresh 
frozen 
SCC/AC/others 18 
 
Kato et al. 
(75) 
Japan 42 2012 16.7 FFPE SCC/AC/others 16,58 
 
Kawaguchi et 
al. (76) 
Japan 876 2016 0.3 FFPE SCC/AC 16,62,66 
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Kinoshita et 
al. (77) 
Japan 36 1995 8.0 FFPE, 
fresh 
frozen 
SCC/AC 18 
 
Lee et al. (78) Korea 233 2016 0 FFPE SCC/AC none 
 
Li et al. (79) China 50 1995 32.0 FFPE, 
fresh 
frozen 
SCC/AC/others 16,18 
 
Lin et al. (80) Taiwan 57 2005 50.9 FFPE SCC/AC 16,18 
 
Lu et al. (81) China 72 2016 45.8 FFPE SCC/AC 16,18 
 
Miyagi et al. 
(82) 
Japan 121 2001 33.9 FFPE SCC/AC 6,16,18 
 
Nadji et al. 
(83) 
Iran 129 2007 25.6 FFPE SCC/AC/others 6,11,26, 
31,16,18 
 
Ogura et al. 
(84) 
Japan 29 1993 10.3 fresh 
frozen 
SCC 16,18 
 
Park et al. 
(85) 
Korea 112 2007 53.6  AC/NSCLC 16,18,33 
 
Wang et al. 
(86) 
Taiwan 153 2006 45.1 fresh  SCC/AC 16,18 
 
Wang et al. 
(87) 
China 313 2008 44.1 fresh 
frozen 
SCC/AC 16,18 
 
Wang et al. 
(88) 
China 45 2010 42.2 fresh 
frozen 
SCC 16,18 
 
Xing et al. 
(89) 
China 49 1993 14.2 FFPE SCC 6,11,16 
 
Yang et al. 
(90) 
China 50 1998 26.0 FFPE SCC 16 
 
Yu et al. (91) China 180 2015 55.6 FFPE SCC/AC/SCLC 16,18 
 
Zhang et al 
(92) China 68 2009 44.1 
fresh 
frozen SCC, AC 16,18 
 
Zhang et al 
(93) China 104 2010 17.3 FFPE 
SCC/AC/others 
 
16 
Total   5222      
 
Table 5: Asian studies 
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From Asia 35 studies were included containing 5222 patients. Two of those were done on 
patients in multiple Asian countries. The country most prevalent is Japan (n=11), followed by 
China (n=10) and Taiwan (n=4). 
32 of these were published in English and three were published in Chinese. Of all the studies 
published in Asia, 34 were journal articles and one was an abstract. 
NSCLC tumor specimens were analyzed in 30 of the included Asian studies. In one study 
only SCLC samples were analyzed. (66) Six of the studies only included SCC samples (65, 
67, 84, 88-90). Two studies only included adenocarcinomas (68, 72).  
The processing method of the analyzed tissue was not detailed in three of the included studies 
(61, 71, 85). Of all the included studies 25 used formalin-fixed paraffin-embedded tissue 
(71.4 %), of the remaining studies nine used fresh frozen tissue. One study analyzed fresh 
tumor specimens (86). In three studies tissue was analyzed in both processing forms (FFPE 
and fresh frozen) (62, 77, 79). 
Information on the used primers was available in 14 studies (40 %). The consensus primers 
MY09/MY11 were used in five cases as the most commonly used PCR primer. 
The number of case-control studies was ten out of the 35 included Asian studies. The total 
number of cases included in these studies was 1401, the number of controls was 538. The 
number of HPV positive cases and controls was 522 and 39 respectively. The overall HPV 
prevalence was calculated to be 37.3 % in the lung cancer cases compared to 7.2 % in the 
control cases from benign lung disease. 
Only 12 of the studies provided data on the patients’ age. The average age was 60.8 years 
with a standard deviation of 5.7 years. 
Information on the patients’ gender was available in 23 of the included studies. 2058 of the 
patients were male and 1265 were female (61.9 %/38.1 %) 
Smoking behavior was detailed in 17 studies. 37.7 % were current or former smoker, 31.2 % 
were never smokers and in 31.1 % the information was not available. 
26 studies contained information on the tissue sampling method. It was resected lung tissue in 
24 studies and seven studies used bronchoscopic biopsies. Six of the studies analyzed both 
surgically resected lung tissue and bronchoscopic biopsies. In one study autopsy material was 
analyzed as well as surgically resected lung tissue (77). In eight of the studies no data on the 
tissue sampling method was available. 
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The total number of cases included from Asia was 5222. The maximum number of cases in 
one of the studies was 901 (71), the minimal amount was nine patients (69). On average there 
were 149.2 patients per study. 
The most prevalent HPV subtype detected was HPV 16 (n=25), followed by HPV 18 (n=19). 
In two studies the HPV subtype was not determined. 
Of all included cases 879 were HPV positive by PCR. The HPV prevalence in the Asian 
subgroup was calculated to be 16.8 %. In four studies no HPV DNA was detected (66, 72, 74, 
78). The highest detected HPV prevalence in one of the studies was 60.3 % (67). 
22 of the studies included data on HPV 16 prevalence. A total of 2946 cases from the 
included Asian studies were tested for HPV 16 DNA. 227 (7.7 %) were tested to be positive. 
Of all included studies 18 reported data on HPV 18 prevalence. Of the 2580 cases 127 were 
positive (4.9 %). 
 
 Positive Negative Total 
HPV 16 227 2719 2946 
HPV 18 127 2453 2580 
 354 5172 5526 
 
Table 6: HPV 16 and 18 prevalence in Asia compared 
 
In the comparison of HPV 16 and 18 prevalence in the studies included in this systematic 
review, there was a statistically significant difference (p<0.01). 
21 of the included studies provided data on HPV prevalence of primary SCC of the lung. 
There were 1331 cases in Asia. 392 of the tumors were tested to be HPV positive (29.5 %). 12 
studies provided information on HPV 16 prevalence in SCCs from Asia. Of the analyzed 561 
cases 101 were positive for HPV 16 (18.1 %). Only 9 studies provided information on HPV 
18 detection. 44 of the analyzed 428 cases were positive resulting in a prevalence of 10.3 %. 
18 of the included studies from Asia analyzed primary adenocarcinomas, including 1226 
cases. The HPV prevalence was 10.4 %. HPV 16 (n=12) and HPV 18 (n=10) prevalence in 
ACs was 8.7 % and 7.3 %, respectively. 
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 HPV 
positive 
HPV 
negative 
Total 
SCC 392 939 1331 
AC 128 1098 1226 
 520 2037 2557 
 
Table 7 HPV prevalence in SCC and AC in Asia compared 
 
There was a statistically significant difference between the HPV prevalence in SCC and AC 
analyzed in the included studies from Asia (p<0.01). 
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6.1.5.3 The Americas 
 
 
Reference Country 
No. 
of 
Cases 
Year 
HPV 
prevalence 
in % 
Specimen 
type used 
Histologic 
subtypes 
tested 
HPV types 
detected 
 
Aguayo et al. 
(94) 
Chile 69 2007 29.0 FFPE SCC/AC/others 6,16,18, 
31,45 
 
Badillo-
Almaraz et 
al. (95) 
Mexico 39 2013 41.0  SCC/AC 16,18 
 
Bohlmeyer 
et al. (96) 
USA 34 1998 5.9 FFPE SCC 18 
 
Cardona et 
al. (97) 
multiple 
South 
American 
countries 
132 2013 39.4 FFPE AC 16 
 
Carlson et al. 
(98) 
USA 12 2007 0 FFPE SCLC none 
 
Castillo et al. 
(99) 
Peru/ 
Colombia/ 
Mexico 
36 2006 28.0 FFPE SCC/AC/others 16,18, 
33 
 
Garcia 
Falcone et al. 
(100) 
Argentina 40 2017 25.0 FFPE SCC 16,18 
 
Joh et al. 
(101) 
USA 30 2010 16.7 FFPE SCC/AC/others 11,16, 
other 
 
Koshiol et al. 
(102) 
USA 399 2011 0 FFPE, 
ethanol 
fixed 
SCC/AC none 
 
Mehra et al. 
(103) 
USA 36 2013 11.0  SCC/AC 16,18 
 
Pillai et al. 
(104) 
USA 208 2013 14.9 FFPE NSCLC 16,18 
 
Rezazadeh et 
al. (105) 
USA 16 2008 25.0 FFPE NSCLC 11,16 
 
Robinson et 
al. (106) 
USA 70 2016 42.9 fresh 
frozen 
SCC/AC 16,18,39, 
44,51,52,68 
 
Suh et al. 
(107) 
USA 48 2010 2.0 FFPE SCC no data 
 
Yanagawa et 
al. (108) 
Canada 336 2013 1.5 FFPE SCC/AC 16 
Total   1505      
 
Table 8: American studies 
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There were 15 studies included that were done on patients from the American continent. Two 
of those studies contained patients from multiple countries. Of the remaining studies ten were 
carried out in North America, one in Middle America and two in South America. 
These studies all were published in English. There were nine journal articles, four abstracts, 
one meeting abstract and one poster presentation. 
All of the included studies but one analyzed NSCLC tumor specimens. One study only 
analyzed specimens of small cell lung cancer. Only one study was a case-control study. It 
only includes ten cases of benign lung disease as control. (106) 
12 studies were performed with formalin-fixed paraffin-embedded tissue specimens, one with 
fresh frozen tissue and two studies did not provide information on the tissue processing 
method. Only five of the studies contained information on the PCR primer used. 
Of the included studies four provided information on the patient age. The average age was 
60.85 years (SD: 5.2).  
Twelve of the included studies provided information on the patients’ gender. 763 were male 
and 464 female, 62.2% and 37.8% respectively. 
Three of the included studies provided information on smoking behavior (94, 96, 102). Of all 
included patients 30.0 % were current or former smokers, 2.8 % never-smokers and for 67.2 
% of patients no information on smoking behavior was available. 
The tissue sampling method was surgical resection in six cases, bronchoscopic biopsy in one 
case, archived tumor tissue in one case and in one case both resected lung tissue specimens 
and bronchoscopic biopsies. No data on the tissue sampling method was available in six 
cases. 
The total number of cases in this subgroup was 1505. The largest study included 399 cases, 
the smallest included 12 cases. On average there were 100.3 cases per study. 
The most commonly detected HPV subtype was HPV 16 (n=10), followed by HPV 18 (n=8). 
Low risk HPV subtypes were detected in three studies. (94, 101, 106) 
Of all those cases 175 were detected to be HPV positive by PCR. The remaining 1330 cases 
showed no sign of HPV DNA. The HPV prevalence was detected to be 11.6 %. The highest 
detected HPV prevalence in any of the American studies was 42.9 % in a study by Robinson 
et al. from 2016 (106). 
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Of the included 15 studies 11 provided data on HPV 16 prevalence. 89 of the analyzed 1110 
cases were HPV 16 positive (8.0 %). Nine of the included studies did PCR to detect HPV 18 
DNA. Of the 642 cases analyzed under this aspect 12 were positive (1.9%). Four of the 
studies stated the HPV 18 prevalence to be zero. (98, 101, 102, 105) One of the studies did 
not provide information on the HPV subtype detected (107). 
 
 Positive Negative  
HPV 
16 
89 1021 1110 
HPV 
18 
12 630 642 
 101 1654 1752 
 
Table 9: HPV 16 and 18 prevalence in the Americas compared 
 
The difference detected between HPV 16 and HPV 18 prevalence detected in the American 
studies was statistically significant (p<0.01). 
Ten of the included studies provided data on HPV prevalence of primary SCC of the lung. 
There were 500 cases in American studies. 54 of those cases were positive and 446 were 
negative. The HPV prevalence in SCC was determined to be 10.8 %. Eight of the included 
studies provided data on HPV 16 prevalence in SCC; it was calculated to be 6.4 %. Seven 
studies provided data on HPV 18 prevalence. 290 cases of SCC were analyzed. Of those 11 
cases were positive for HPV 18 DNA (3.8%). 
Only eight studies provided information on adenocarcinomas of the lung. Cumulative there 
were 680 cases of AC analyzed. 78 of them were determined to be HPV positive (11.5 %). 
Only three studies contained information of HPV 16 prevalence in AC. Two of them were 
negative. (102, 108) The highest HPV 16 prevalence was 39.4 %. (97) Only two studies 
contained data on HPV 18 prevalence. It was determined to be zero (102) and 15.4% (99) 
respectively. 
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 HPV 
positive 
HPV 
negative 
 
SCC 54 446 500 
AC 78 602 680 
 132 1048 1180 
 
Table 10: HPV prevalence in SCC and AC in the Americas compared 
 
The difference between the HPV prevalence in SCC and AC was not statistically significant 
(p=0.78). 
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6.1.5.4 Continents compared 
 
 
 Europe Asia The Americas Total 
Number of 
cases 
2226 5222 1505 8953 
Number of 
HPV positive 
cases 
168 879 175 1222 
HPV 16 
positive cases 
61 227 89 337 
HPV 18 
positive cases 
11 127 12 150 
HPV 
prevalence  
7.5% 16.8% 11.6% 13.6% 
HPV 16 
prevalence 
3.9% 7.7% 8.0% 6.0% 
HPV 18 
prevalence 
0.8% 4.9% 1.9% 3.2% 
 
Table 11: HPV prevalence on continents 
 
A total number of 8953 lung cancer patients was included into this systematic review. Most of 
the cases included were analyzed in Asia. In total 58.3 % of cases were from Asia, 24.9 % of 
cases were from Europe and 16.8 % of cases from The Americas. 
In the biopsies of all included patients with lung cancer HPV was detected to be positive in 
1222 cases. The overall HPV prevalence was calculated to be 13.6 %. The highest HPV 
prevalence was detected in Asia with 16.8 %, followed by The Americas (11.6%) and Europe 
(7.5 %). 
On all three continents the calculated prevalence of HPV 16 was higher than for HPV 18. The 
highest HPV 16 prevalence was detected in the Americas (8.0 %), followed by Asia (7.7 %), 
and Europe (3.9%). Overall the HPV 16 prevalence was calculated to be 6.0 %.  
The calculated HPV 18 prevalence was calculated to be 3.2 %. The highest HPV 18 
prevalence was found in Asia (4.9 %) followed by the Americas (1.9 %) and finally Europe 
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(0.8 %). The difference between the HPV 16 and HPV 18 prevalence detected worldwide was 
statistically highly significant (p<0.01). 
The difference between the HPV prevalence for all HPV subtypes combined was statistically 
significant when the HPV prevalence in Europe was compared with the HPV prevalence in 
Asia or the Americas, as well as when the Asian and American HPV prevalence was 
compared (p<0.01 in each case). 
 
6.1.6 Squamous Cell Carcinoma vs. Adenocarcinomas 
 
 Europe Asia America Total 
Number SCC 798 1331 500 2629 
Number SCC 
HPV positive 
43 392 54 489 
Number AC 763 1226 680 2669 
Number AC 
HPV positive 
52 127 78 257 
HPV prevalence 
SCC 
5.4% 29.5% 10.8% 18.6% 
HPV prevalence 
AC 
6.8% 10.4% 11.5% 9.6% 
 
Table 12: HPV prevalence SCC vs. AC 
 
Of all the included 8953 lung cancer cases 2629 were squamous cell carcinomas and 2669 
were adenocarcinomas. For the remaining 3655 case no detailed information was on histology 
was available or they were classified as NSCLC without further specification. Most of these 
cases in both groups were from Asia. 
The overall HPV prevalence in SCC (n=489) was calculated to be 18.6 %. The highest 
prevalence was calculated in Asia (29.5 %). The lowest in Europe (5.4 %). 
In contrast the highest HPV prevalence in AC was calculated in The Americas (11.5 %), 
followed by Asia (10.4 %) and Europe (6.8 %). The overall HPV prevalence in 
adenocarcinomas (n=257) was calculated to be 9.6 %.  
The HPV prevalence in SCC and AC was the lowest in both subgroups in Europe. 
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To analyze the differences between detected HPV prevalence in SCC and AC the provided 
HPV prevalence detailed in the included studies was compared. The highest identified HPV 
prevalence in SCC in one of the studies was 60.3 % (67) in a study from Japan from 1996. 
The highest HPV prevalence in AC was 55.5 % (95) in a study from Mexico from 2013. 
 
 HPV 
positive 
HPV 
negative 
 
SCC 489 2140 2629 
AC 257 2412 2669 
 746 4552 5298 
 
Table 13: HPV prevalence SCC vs. AC worldwide compared 
 
When the provided HPV prevalence of SCC and AC are compared the difference is 
statistically highly significant (p<0.01). 
 
6.1.7 Cases vs. Controls 
 
 Case group Control group 
Number of cases 1750 754 
Number of HPV detections 548 41 
HPV prevalence 31.3% 5.4% 
 
Table 14: HPV prevalence Case vs. Control Group 
 
Of the included studies 15 are case-control studies (Appendix Table 11). One of them is from 
America, ten are from Asia and four from Europe.  
In all of those studies 1750 lung cancer cases and 754 controls were analyzed. The number of 
HPV positive cases and controls was 548 vs. 41 respectively. The HPV prevalence was 
detected to be 31.3 % in the lung cancer group and 5.4 % in the control group. 
The difference of the detected HPV prevalence between the case group and the control group 
was statistically highly significant (p<0.01). 
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 Europe Asia America Total 
Number cases 279 1401 70 1750 
Number HPV 
positive cases 
17 522 9 548 
Number controls 206 583 10 754 
Number HPV 
positive controls 
1 39 1 41 
HPV prevalence 
cases 
6.0% 37.3% 12.9% 31.3% 
HPV prevalence 
controls 
0.5% 6.7% 10% 5.4% 
 
Table 15: Case-Control studies on the different continents 
 
When the difference between cases and controls is compared separately in each of the 
continents, it is statistically significant as well in Europe as in Asia. Only one case-control 
study from The Americas was included. 
 
6.1.8 FFPE vs. fresh frozen 
 
 FFPE Fresh frozen 
Number of studies 40 15 
Number of cases 4476 1763 
Number of HPV detections 599 238 
HPV prevalence 13.4% 13.5% 
 
Table 16: HPV prevalence in FFPE and fresh frozen tissue 
 
40 of all included studies analyzed solitarily formalin-fixed paraffin-embedded tissue. 
(Appendix Table 12) 
The total number of included cases was 4476. In the FFPE cases the number of HPV 
detection was 599 which leads to a HPV prevalence of 13.4 %. 
15 of the included studies analyzed fresh frozen tumor tissue. (Appendix Table 13) 
The number of fresh frozen tumor tissue cases analyzed in these studies was 1763 of which 
238 were found to be positive. The HPV prevalence was calculated to be 13.5 %. 
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The difference between the HPV prevalence detected in the studies was not statistically 
significant between the FFPE and fresh frozen tissue (p=0.9). 
 
6.1.9 1990s vs 21st century 
 
 1990s 21st century 
Number of studies 6 26 
Total number of cases 425 4005 
Number of HPV positive 
cases 
161 339 
HPV prevalence 37.9% 8.5% 
 
Table 17: HPV prevalence in studies from the 1990s and 21st century 
 
Six of the included studies were conducted in the 1990s. (Appendix Table 14) Of the 425 
cases 161 were positive by PCR. The calculated HPV prevalence was 37.9 %. 
Of all the included 73 studies 26 were done in the 21st century. (Appendix Table 15) A total 
of 4005 cases were analyzed. The number of positive cases was 339 which sums up to a HPV 
prevalence of 8.5 %. 
The difference between the HPV prevalence stated in both subgroups was statistically highly 
significant (p<0.01). 
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6.2 Experimental Part 
 
6.2.1 Patient Characteristics 
 
A total of 16 tissue samples of 14 patients were included. The average age of the included 
patients was 69.6 years (SD: 9.6). 57 % are male (8/14) and 43 % female. Information on 
smoking behavior was available for all but one patient. There were five current smokers and 
eight former smokers. The average number of pack years was 65 for the current smokers at 
time of diagnosis and 39 for the former smokers, respectively. 43 % were previously 
diagnosed with COPD. All of them were diagnosed with primary lung cancer between 2017 
and 2018 and have been operated on by the Department of Thoracic Surgery at the University 
Clinic Regensburg. 
 
Table 18: Patient characteristics 
 
  Total number 
of patients 
Range Percentage 
Total number 
of patients 
 14   
Mean age 
(range) years 
 69.6 
 
60.0 - 79.2  
Sex     
 male 8  57.0 
 female 6  43.0 
Tumor 
histology 
 
   
 squamous cell 
carcinoma 
14  100 
Smoking 
behavior 
 
   
 current 
smokers 
5  35.7 
 former smokers 8  57.2 
 no information 1  7.1 
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Histology was determined to be squamous cell carcinoma in all 14 patients. As an example 
for the light microscopic picture two photographs of an included tumor sample of primary 
SCC of the lung are documented here. They are taken with a microscopic enlargement of 40 
and 100 fold respectively. Both pictures were taken by Dr. Kirsten Utpatel, Department of 
Pathology University Clinic Regensburg using a Nikon Eclipse Ci microscope. 
 
 
Figure 1: Histology SCC 40 fold 
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Figure 2: Histology SCC 100 fold 
 
 
 
 
 6.2.2 HPV Detection 
 
All of the analyzed tumor biopsies were negative for HPV by nested PCR (0/14). The 
prevalence of HPV infection in SCC detected by nested PCR in our sample was zero percent. 
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7. Discussion 
 
Case-Control studies 
 
In the literature the question of a possible causality between HPV infection and lung cancer is 
discussed very critically. To further evaluate this topic case-control studies on HPV 
prevalence in both lung cancer samples and benign lung disease samples have been done in 
different countries. 
In a case-control study conducted by Zhang et al. (92) in 2009 HPV was detected in 44.1 % of 
lung cancer cases and 8.3 % of benign lung disease respectively which shows a significant 
difference. They concluded that HPV is an important risk factor for lung cancer development. 
While studies like these have been showing significant difference of HPV infection levels in 
Asia, the studies done in the other parts of the world have not been as distinct. 
In another case-control study from Iran (83) the prevalence of HPV DNA was significantly 
higher  in the case group compared to the control group, 25.6 % vs. 9 % respectively, as well. 
The control group consisted of patients with lung diseases other than cancer. Even though the 
HPV prevalence in the lung cancer group is significantly lower than in the Chinese study, the 
prevalence in the control group is on a similar level. 
Both studies used samples from patients with benign lung disease as controls. One of the 
problems with these samples could be that the risk factors for those diseases are the same as 
for the development of lung cancer, e.g. smoking. Some publications have discussed an 
association between smoking and HPV infection due to the higher vulnerability of the 
bronchial epithelium. In this case smoking might be the initiating factor for the development 
of lung cancer and HPV infection might only follow as a co-factor. 
In a European case-control study carried out in Italy and the United Kingdom 100 tissue 
samples of primary SCCs of the lung and adherent non neoplastic lung tissue (n=85) were 
tested for the presence of HPV DNA. (42) There was no HPV DNA detected, neither in the 
tumor nor in the control samples. Since the positive control for DNA quality was successfully 
amplified, all tested specimens were declared free of HPV infection. 
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This might indicate that in fact HPV in lung tissue, whether malignant or not, is not very 
common in Europe. Our study result on primary SCC samples is in concordance with these 
results. 
In this systematic review the difference between HPV positive cases and controls was 
statistically significant, 31.3 % versus 5.4 % (p<0.01). When the difference between cases and 
controls is compared separately in each of the continents, it is statistically significant as well 
in Europe as in Asia. Only one case-control study from The Americas was included (106). 
The difference in HPV prevalence was statistically significant. 
But there have also been studies that did not find a statistical difference between the HPV 
prevalence detected in lung cancer cases and control samples. An Italian study on 50 cases of 
primary SCC of the lung and 23 control cases of wedge resections for non-neoplastic 
pneumothorax the HPV prevalence was detected to be 4 % and 4.3 % respectively. (43) Even 
though the number of cases was relatively low it shows presence of HPV DNA in squamous 
cell carcinoma of the lung, but not statistically significant when compared to non-neoplastic 
lung tissue. 
There is a strong indication that HPV prevalence in lung cancer is higher than in benign lung 
tissue even though there have been some studies which established contradictory results. 
Whether HPV prevalence does play a causal role in lung cancer development is not yet 
decided either. 
 
Studies from Germany and other European Countries 
 
In a study conducted in France by Thomas et al. HPV prevalence was detected to be 16 % 
(109), which is a lot lower than the average detection rates in Asia.  
Miasko et al. found a similar HPV prevalence conducted in Poland in two separate studies of 
10 % and 12.7 % respectively. (46, 47) In these studies low risk as well as high risk HPV 
subtypes were detected. 
To this day only one study conducted in Germany showed HPV DNA in primary lung tumor 
tissue. (41) Eberlein-Gonska et al. tested primary lung cancer tissue of 50 patients and 15 
biopsies of normal bronchial mucosa in 1992. HPV DNA was detected two cases of SCC and 
one case of AC by PCR. None of the control biopsies were positive. Two other studies 
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conducted in Germany met the inclusion criteria (52, 57). Neither of them detected HPV 
DNA in the tested lung cancer tissue.  
The only Dutch study that met the inclusion criteria (55) detected no HPV DNA in 211 cases 
of primary lung cancer by PCR with consensus primers GP5+/GP6+ in 2013. 
In another French study carried out in 2005 HPV prevalence was found to be only 1.8 % in 
NSCLC. (40) Of all the 218 cases only four were positive for HPV 16. A Polish study from 
2012 showed HPV DNA only in one of 33 cases and the one detected was HPV 120. (49) 
A Finish study from 2012 did detect HPV DNA in primary lung cancer cases even though the 
prevalence was low 5.2 % (54). 
Another Greek study analyzed 67 tumor samples of NSCLC for presence of HPV DNA and 
E6/7 mRNA. (37) Two of the tumor samples were detected to contain HPV DNA but the 
corresponding test for mRNA turned out to be negative. Only few studies have tested tumor 
samples for active transcription of mRNA. The authors concluded that most likely, at least in 
this population, HPV DNA does not play a role in lung cancer development. More studies 
should be done including detection of active protein transcription of HPV. Thereby a better 
understanding of the role of HPV in the tested tissue could be gathered and a better 
understanding of its possible role in carcinogenesis could be gained. 
The highest detection rate for HPV was found in a study conducted in Greece as well (48). In 
this study 52 cases of SCC were tested for the presence of HPV by PCR using consensus 
primers followed by Southern blot hybridization. 21 cases showed positivity by PCR (40 %). 
Another Greek study by Sarchianaki et al. found HPV prevalence to be 19 % (51) which is the 
second highest HPV prevalence found in Europe. This might indicate that there is a 
geographic difference in the distribution of HPV infection within Europe similar to the 
geographic difference in HPV prevalence in Asia compared to Europe. 
It has to be noticed that in the included study from neighboring Turkey the detected HPV 
prevalence was only 5.0 % (58). Another Turkish study conducted by Zafer et al. (58) 
detected HPV in 2 out of 40 non-small cell lung cancers. Both were squamous cell 
carcinomas and all the included patients were smokers. 
In general there seems to be a lower rate of HPV detection rates in Europe with some 
difference in geographic distribution. Germany to this day is one of the countries with the 
lowest HPV detection rates in Europe and worldwide. 
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Tissue sampling and processing method 
 
An American study on a cohort of 399 primary SCC and AC of the lung did not detect any 
HPV DNA either. (102) Testing was done on formalin-fixed and ethanol-fixed tissue 
specimens. A difference in detected HPV prevalence depending on the tissue processing has 
been previously discussed. The most common tissue processing method is formalin-fixed 
paraffin-embedded tissue because it is the method used most often to store tissue samples for 
long periods of time. Some scientists have annotated that certain parts of HPV DNA might be 
lost during this processing which might explain the low HPV prevalence in certain studies 
depending on the tissue processing methods used. 
In another study done on archival tumor tissue in the United States HPV DNA prevalence was 
detected to be 16.7 %. (101) All of the tumor specimens employed in their study were 
obtained from the Tumor Tissue Bank at the University of Louisville. They were stored not as 
paraffin-embedded samples but in their frozen form. This might be a possible explanation for 
the higher detection rate of HPV DNA. 
Some of the included studies analyzed tissue samples processed in both ways (36, 48, 62, 77, 
79). Unfortunately none of these studies directly compared the detected HPV prevalence in 
tissue processed either way. The results were reported as one. 
In our systematic review the detected HPV prevalence in FFPE and fresh frozen lung cancer 
samples was almost identical 13.4 % and 13.5 % respectively. The difference was not 
statistically significant. 
Another aspect of the analyzed tumor tissue specimens that has to be taken into account is the 
tissue sampling method. Most of the included studies analyzed HPV in resected lung tissue. 
The second most common tissue sampling method is bronchoscopic biopsy. The histological 
samples obtained by operation provide a lot more tissue which allows for several rounds of 
PCR detection if needed. It also allows for samples to be stored for later analysis. 
Another factor that might bias the results is that operative lung resection is only done in early 
stage or locally advanced lung cancers. Even though only few of the included studies 
provided information on the lung cancer stage of the included patients, it has to be assumed 
that those were not stage IV cancer patients since they have no indication for lung resection. 
There might be a possible association between HPV infection and tumor stage which might 
not be resembled in this systematic review. 
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Our own analysis was done on resected lung tissue that was formalin-fixed and paraffin-
embedded which is the most common tissue specimen analyzed in the included studies. Still 
we did not detect HPV DNA by nested PCR. 
 
Histological subtypes 
 
Some authors have discussed whether HPV infection might be more strongly related with a 
specific histological subtype of lung cancer. 
A study conducted on 313 fresh frozen lung cancer samples from central China in 2008 
analyzed 215 SCCs and 98 ACs. The HPV prevalence in SCC was significantly higher than 
that in AC, 52.1 % vs. 26.5 % respectively. 
In contrast a study from Norway (50) showed a significantly higher HPV prevalence in lung 
adenocarcinoma compared to squamous cell carcinoma, e.g. 5,6 % and 1,2 % respectively. 
Even though the detected HPV prevalence in Europe is lower than in many Asian studies. 
There are several studies from Asia showing a higher HPV prevalence in lung 
adenocarcinomas than in squamous cell carcinomas. (60, 62)  
In contrast a study conducted by Iwakawa et al. on 297 primary adenocarcinomas of the lung 
in Japan in 2010 did not detect any HPV DNA in any of the samples. (72) To exclude 
possible wrong negative results because of the implemented detection method they tested the 
tumor samples with both nested PCR and a one-step multiplex PCR with type specific 
primers. Both detection methods showed negative results, so that the authors came to the 
conclusion that the results were not based on low sensitivity of any of the methods as it had 
been previously described by other scientists. 
Only very few studies included primary SCLC of the lung into their analysis. A small study 
from the USA conducted in 2007 analyzed 12 tumor biopsies of primary SCLC of the lung. 
No HPV DNA was detected in any of them. (98) Since there is a strong association between 
SCLC and smoking behavior the HPV prevalence in SCLC would be expected to be higher if 
HPV infection was in fact connected to smoking behavior. The data available in the literature 
on this topic is scarce so that no real trend can be derived from it. 
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An association specifically between SCC and HPV infection has been discussed since an 
association between squamous cell carcinomas and HPV in other organs sites has been 
shown. To this day the data is not conclusive on this question.  
In our own experiments we did not detect HPV DNA in primary SCC of the lung by nested 
PCR. In this systematic review the difference between HPV prevalence in SCC and AC was 
statistically highly significant (p<0.01). The higher HPV prevalence was detected in SCC. 
The same is true if all continents are analyzed individually even though the difference 
between the individual HPV prevalence in the subgroups was only statistically significant in 
Asia (p<0.01). 
 
HPV Subtypes 
 
Regional differences in the distribution of different HPV subtypes have been discussed 
previously. Park et al. found a significantly higher prevalence of HPV 33 compared to HPV 
16 and 18 in a study conducted on NSCLC samples from Korea. (85) 
Another case-control study from China detected HPV 18 to be the most dominant type of 
HPV in NSCLC. HPV detection rate was significantly higher in the lung cancer group 
compared to the control group and was associated with the degree of histological 
differentiation and lymph node metastasis and thereby tumor stadium. (81) 
In a study conducted in Iran in 2013 no HPV 16 DNA was detected but the prevalence of 
HPV 18 was 16 %. (73) In this study only Squamous Cell Carcinomas were included which 
are known to be closely related to smoking behavior. Until now no correlation between 
smoking and special subtypes of HPV has been found. 
In contrast a study conducted in China and Pakistan only HPV 16 was detected in 60 cases of 
primary lung carcinoma. (59) All of these were cases were Squamous Cell Carcinoma. 
In our systematic review the HPV prevalence of HPV 16 was higher than the HPV 18 
prevalence in all continents, 6.0% and 3.2% respectively. The difference was statistically 
highly significant (p<0.01). The same is true if all continents are analyzed separately.  
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Detection method 
 
There is huge variety of HPV prevalence in the lung detected in the included studies and in 
other literature reflecting on the topic. The detection methods mostly used for HPV detection 
are PCR and ISH.  
A Chinese study analyzed 141 NSCLC tumor specimens with both nested PCR and in situ 
hybridization (ISH). (62) The concordance between HPV 16 and HPV 18 detection by PCR 
and ISH were 73% and 85,5% respectively. In both cases the HPV detection rates acquired by 
nested PCR were higher. In this study not only two different detection methods were used but 
the tissue was previously processed in two different ways: formalin-fixed paraffin-embedded 
and fresh frozen. Unfortunately no formalin-fixed probes of the non-lung cancer tissue were 
available. No HPV DNA was detected in the control group. 
In a study from The Americas the concordance rate between ISH and PCR was 100 %. (108) 
The overall HPV prevalence in this study was only 1.5 %. 
There has been some discussion about low specificity in PCR, which might lead to false 
negative results and as a final result to a higher HPV prevalence detected. While PCR is in 
fact a very sensitive method it does not allow to analyze which kind of cells etc. are infected 
by HPV but only provides the information that HPV DNA is included in the analyzed sample. 
A study conducted in 2012 tested both lung tumor tissue and adjacent non-tumor tissue from 
the same patients by PCR using primers detecting the L1 region of HPV. They did not detect 
HPV in neither cases nor adjacent tissue. 
Not only different detection methods but also differences between the executions of the 
methods could play a role in discrepancies of HPV prevalence detected. 
A study from Bulgaria detected HPV prevalence in lung cancer samples by three parallel 
PCRs. They used the consensus primer GP5+/6+ and type-specific primers for HPV 16 and 
18. The HPV prevalence detected by type-specific primers was higher than by consensus 
primers, 25 % vs. 3.8 % respectively. (110) 
In our systematic review not enough studies provided information on the used PCR primers to 
calculate the differences in the resulting HPV prevalence detected. Only 26 of the included 
studies contained information on the PCR primers used. There was a huge variety of primers 
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used with MY09/MY11 and GP5+/6+ being ones most frequently implemented. 
Unfortunately the number of different primers used resulted in subgroups that were too small 
to provide statistically reliable results. 
Many discrepant results have been published on the subject of HPV prevalence in lung cancer 
over the years. To create a more uniform group of studies for our systematic review we only 
included studies using PCR as detection method. Still there was a huge variability of HPV 
prevalence in the studies meeting the inclusion criteria. 
In the last 30 years PCR technology has evolved. To understand whether this development 
has had an effect on the detected HPV prevalence the included studies conducted in the 1990s 
and those conducted in the 21st century were analyzed separately and the results were 
compared. The HPV prevalance detected in the studies conducted in the 1990s was higher 
than in the studies conducted in the 21st century, 37.9 % and 8.5 % respectively. The 
difference was statistically highly significant (p<0.01). PCR technique has developed and new 
methods like e.g. nested PCR are more frequently applied which might lead to a higher 
sensitivity. In our own analyzes we used nested PCR but did not detect HPV DNA in any of 
the samples. 
It also has to be taken into consideration that the methods applied to detect HPV DNA in the 
included studies have been evaluated by analyzing cervical cancer specimens. Due to the 
biological difference between cervical and lung tissue there might be some difference in 
sensitivity and specificity of the applied methods. 
In our study the tissue processing method did not make a statistical difference on the HPV 
prevalence. Some studies have discussed that certain parts of the HPV genome might be lost 
if the tissue is paraffin-embedded. If the primers engaged are using this regions as an aim the 
results would be false negative. There are no studies proving such a theory to our knowledge 
but it has to be taken into consideration when comparing study results. 
 
Previous history of malignancy 
 
One of the theories that has been discussed is that HPV prevalence might not be a marker for 
HPV infection but for a possible metastatic disease. This could be the case for example in 
women suffering from cervical intraepithelial lesions or cervical squamous cell cancers who 
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have gone undiagnosed. Many of the included studies did not provide information on previous 
malignancies of the included patients.  
A Norwegian study from 1999 compared HPV prevalence in women with both CIN III 
(cervical intraepithelial neoplasia) lesion and second primary cancers of the lung compared to 
women with primary lung cancers without previous history of CIN. (45) There results indicate 
that HPV might be a factor in both CIN III lesions and second primary lung cancers after CIN 
III lesions. Even though the HPV prevalence in the control group was lower than in the group 
of the secondary bronchopulmonary carcinomas (14 % and 32 % respectively), the difference 
was not significant (p=0.13). In this study only low risk HPV subtype 6 was detected in the 
control group which has to be taken into consideration. 
In Canada a study on NSCLC cases was conducted in 2013. (108) Yanagawa et al. tested 
HPV prevalence in 336 cases of surgically resected primary NSCLC. All samples were 
formalin-fixed paraffin-embedded and histology was determined to be SCC in 132 and AC in 
203. This study showed a low HPV prevalence in NSCLC in North American patients. Even 
though all included tissue samples were classified as primary lung cancers, all of the patients 
who were positive for HPV DNA had a previous history of cervical cancer or head and neck 
cancer. HPV prevalence was detected 1.5 % with all five positive cases being SCC. In this 
study all patients that were found to have a HPV positive tumor had a previous history of 
either head and neck cancer (n=2) or cervical squamous cell carcinoma (n=3). 
In our own study two of the patients did have a previous history of malignant disease. One 
patient previously had a head and neck tumor and the other suffered from thyroid cancer. 
The lungs are one of the most common places of metastatic disease. Differentiation between 
primary lung cancer and metastatic disease is especially difficult if both tumors show the 
same histology in light microscopy. 
A Dutch study conducted in 2013 tried to differentiate tumors presenting in the lung by HPV 
infection. They analyzed both primary lung cancer (from patients without or unrelated 
malignancies in their past) and lung tumors whose origin was not determined at the time of 
diagnosis. None of the primary lung cancers were found to be HPV positive but three of the 
equivocal carcinomas were. All of these patients had a history HPV associated malignancies 
(one tonsillar carcinoma and two cervical carcinomas). 
Since a possible association between primary lung cancer and HPV infection has not been 
excluded a differentiation between lung metastasis and primary lung cancer cannot be made. 
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However if the radiological findings in the lung seem to be those of a metastatic lung disease 
and histological biopsies are obtained, HPV infection could be used as a hint to the possible 
primary since some tumors have been proven to have a strong association to HPV infection 
(e.g. cervical cancer, head and neck cancer, tonsillar cancer). (30) 
 
Detection in different organ sites 
 
Since the association between cervical cancer and HPV infection has been proven a lot of 
research on a possible association between HPV infection and malignancies has been done 
not only concerning lung cancer. 
A study from Pakistan compared the HPV prevalence in lung and breast cancer. (69) The 
HPV detection rate was 11 % and 17 % respectively. HPV has not yet been identified to play 
a significant role in breast cancer but it has been in other organ sites, especially in squamous 
cell carcinomas. 
In an Iranian HPV prevalence study 30 cases of SCC of the lung and oral cavity were 
compared. (65) While three samples in the lung cancer group were detected to be HPV 
positive, six SCCs of the oral cavity were positive. But the difference was not statistically 
significantly higher. 
In a systematic review on head and neck cancer conducted by Kreimer et al. in 2005 the 
overall HPV prevalence was calculated to be 25.9 %. It was significantly higher in 
oropharyngeal SCCs than in oral SCCs and laryngeal SCCs. (111) Almost all detected HPV 
subtypes in this systematic review were HPV 16 or 18. Because of the high HPV prevalence 
detected in head and neck cancers the authors concluded that there might in fact be a causal 
relationship even though it has not been proven yet. Since the risk factors for lung and head 
and neck cancer are similar another possibility might be that HPV infection only plays a role 
as a co-carcinogen in combination with risk factors like smoking for example. 
Some researchers have tried to differentiate between primary lung cancer and metastases from 
previous head and neck SCC. (112) They concluded that HPV DNA could be an additional 
factor that could be useful to differentiate but it cannot be used as a single deciding factor. 
The association between cervical cancer and HPV infection is well established and the 
association with anogenital cancers is commonly accepted. On the other hand a possible 
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association between head and neck cancer and other cancers e.g. breast cancer, bladder 
cancer, esophageal cancer is still subject to ongoing research and no real trends can be seen in 
the literature. 
Possible microscopic correlations of HPV infection 
 
The theory that there might be an association between lung cancer and HPV infection was 
first published by Syrjänen in 1980. (113) Histological findings similar to condyloma of the 
cervix were described and further investigated. 
Since those findings different types of microscopic and electron microscopic investigations in 
lung cancer were described that were discussed to be associated with a possible HPV 
infection. 
One of the observations made for lung cancer in some studies was koilocytosis. Koilocytosis 
is a feature of HPV infection in squamous epithelial cells. (114) Some of the cellular changes 
are: nuclear enlargement, hyperchromasia and a perinuclear halo. 
In a study from China analyzing NSCLC specimens koilocytosis was found in several cases 
that were tested to be HPV positive. (87) In contrast an American study on 34 cases of 
primary SCC of the lung discovered koilocytosis in 11 cases but none of these cases were 
HPV positive by PCR. (96)  
Some publications have reported Langerhans cell infiltration in lung cancer. (115) A study on 
HPV-infected squamous cell carcinoma and adenocarcinoma of the lung detected a high 
Langerhans cell infiltration. (82) The authors discuss that the high Langerhans cell 
infiltrations might be caused by HPV infection. High Langerhans cell infiltration was 
associated with HPV infection in both SCC and AC. In the HPV negative lung cancers the 
Langerhans cell infiltration was lower. In their study SCCs with high Langerhans cell 
infiltration was associated with a better prognosis. Studies on uterine cervical intraepithelial 
neoplasia have focused on Langerhans cell infiltration and even though there are some 
conflicting results, Langerhans cells seem to be HPV antigen-presenting cells. According to 
current knowledge they take part in initiating the immune response. (116) An association 
between smoking behavior and Langerhans cell infiltration has been discussed as well. Since 
smoking is the main risk factor for lung cancer development most of the patients analyzed in 
the studies were smokers.  
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HPV detection in material other than tumor biopsies 
 
To secure lung cancer diagnosis a histological sample is needed. Usually such samples are 
gathered by bronchoscopy either via transbronchial fine needle puncture or by endobronchial 
ultrasound puncture of lymph node metastases. These sampling methods do not provide large 
tumor samples and due to recent advances in research more tests on tumor tissue are made 
e.g. immunohistochemistry, molecular pathology. Since the most established method for HPV 
detection is PCR this means additional tests of the bioptic material can be problematic. For 
this reason some studies have tried to detect HPV infection in less invasive material. 
One possibility is to test cells found in pleural effusions. (117) In the majority of cases 
malignant pleural effusion is caused by lung cancer. (118) Still not all patients with lung 
cancer develop pleural effusion which is associated with a higher tumor stadium and pleural 
effusion very often only provides few tumor cells which can be difficult to process even to 
secure diagnosis. 
In an Italian study by Carpagnano et al. (38) HPV detection by PCR was not only performed 
on tumor tissue but also in exhaled breath condensate (EBC). A total of 12 (16.4 %) of the 
included 89 tumor tissue specimens were detected to positive by PCR. All of them were 
matched with their EBC of which 11 (15.1 %) turned out positive. Not only did these two 
different tested materials provide similar prevalence rates but the detected HPV subtypes were 
the same as well. (e.g. 16, 30, 31, 39) All of the controls turned out negative both in EBC as 
well as in the paired lung tissue. 
Several studies have tested blood samples for presence of HPV DNA. Buyru et al. tested 
blood samples from lung cancer patients and healthy control subjects for the presence of HPV 
DNA by PCR using consensus primers MY09/MY11. (119) They detected HPV DNA only in 
one of 65 patients (HPV prevalence 1.54 %). 
A Chinese study tested serum samples of 183 lung cancer cases and 217 controls for antigen 
specific antibodies. No correlation between HPV 16 L1 or HPV18 L1 seropositivity and lung 
cancer risk was found. (120) These results were consistent with the results found in a study 
analyzing serum samples from the USA conducted by the same researchers. (121) 
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One meeting abstract from 2011 reports an increased lung cancer risk in the presence of HPV 
antibodies in European patients. (122) Unfortunately the abstract provides only very few 
details and a follow-up study could not be found. It reports that in a case-control study the 
serological antibodies for high-risk HPV was statistically significantly higher in lung cancer 
patients than in the control group. The author states that these findings are only descriptive 
and further research has to be done to establish a causal association between serum antibodies 
and lung cancerogenesis. 
No marker for HPV infection in blood samples has been identified yet. According to current 
research HPV does not create viremia so most research is not directed toward detecting HPV 
DNA in blood samples but to find a marker for seropositivity and activity of a possible 
infection. (19) Interpretation of HPV antibodies is difficult since research on CIN has shown 
that HPV infection can be persistent for years in cervical epithelium before causing malignant 
transformation. 
Another approach was tested by Mehra et al. (103) who conducted a pilot study to determine 
whether p16 could be used as a surrogate marker for HPV infection as it has been proposed in 
HNSCC. They detected HPV 16/18 prevalence to be 11 % but found no association with p16 
expression.  
 
Possible association between HPV infection and oncogenic mutations 
 
A Japanese study done in 2016 analyzed the mutational spectrum in newly diagnosed NSCLC 
as well as the prevalence of HPV DNA in 876 lung cancer specimens. (76) The HPV 
prevalence was detected to be only 0.3 % and no association with any of the detected driver 
mutations was found. They did detect the mutational spectrum to be directly related to the 
environmental factors BMI and smoking. Mutations TP53, KRAS, EGFR and SMAD4 were 
proportionally linked to the smoking dose. A possible correlation between smoking dose and 
HPV prevalence as has been discussed by the authors but could not be detected. This might be 
in part because of the extremely low HPV prevalence. 
Another Japanese study from 2012 found a significant correlation between EGFR mutation 
and presence of HPV DNA. (75) HPV prevalence was detected to be 16.7 % in 42 NSCLC 
probes and EGFR mutation was found in 31 %. 
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There have been more studies researching a possible association between EGFR mutations 
and HPV infection and some also focused on the gefitinib-response in that context. Gefitinib 
is a medication used in targeted cancer therapy and belongs to the class of EGFR inhibitors. 
It´s a selective inhibitor of the epidermal growth factor receptor's (EGFR) tyrosine kinase 
domain. 
A Japanese study analyzed gefitinib-response in lung adenocarcinomas with high-risk HPV 
prevalence. (60) High-risk HPV DNA was found in six out of eight gefitinib-responsive 
adenocarcinomas (75 %). None of the 12 remaining adenocarcinomas (without gefitinib-
response) were detected to be HPV positive. Unfortunately EGFR mutations were not tested 
in the screened adenocarcinomas. EGFR is known to be more prevalent in females, never-
smokers and patients of Asian ethnicity.  
In a Chinese study lung cancer tissue samples were analyzed for both HPV infection and 
EGFR mutations. (123) HPV DNA was significantly associated with EGFR mutations. HPV 
prevalence was 28.4 % and 46.3 % had EGFR mutations. These results are in concordance 
with a study conducted by Marquez-Medina et al.. (124) 
EGFR mutations are more common in nonsmoking women from Asia and are strongly 
associated with adenocarcinoma. (125) The reasons behind these findings are not yet 
understood.  
Some authors have discussed that a similar reason might be involved in the higher HPV 
prevalence in nonsmoking women in Asia and the high rate of EGFR mutations. What that 
might be is still undecided and subject to ongoing research. A possible explanation could e.g. 
be an association with ethnicity and hormonal factor. 
In 1996 a Greek researcher group tested for HPV DNA and KRAS mutation in 99 surgically 
resected lung cancers. (53) They detected HPV DNA and KRAS mutation in the same case in 
50 %. The HPV prevalence was 15 %, while KRAS mutation was detected in 18 % of the 
examined specimens. KRAS is the most frequent oncogene driver mutation in NSCLC in the 
western countries. It is associated with smoking and includes different genotypes that are still 
subject to research. (126) KRAS-mutation is associated with poor chemotherapy response so 
that extensive research has been done to develop treatment for these patients. The large 
biological heterogeneity of this mutations makes development of targeted therapies extremely 
difficult.  
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A possible explanation for these findings could be that HPV infection by itself is not 
sufficient for the development of lung cancer but might be involved as a co-factor in 
carcinogenesis. 
 
Detection of active transcription of HPV 
 
Most of the studies done on HPV prevalence in lung cancer use PCR on HPV DNA. It is 
known from studies done on cervical and oropharyngeal cancer specimens that presence of 
HPV DNA does not allow to draw conclusions on a causal relationship. Only few studies 
have tested for active transcription either by the detection of mRNA or the expression of one 
of the viral proteins. (39, 77, 127, 128) 
A study conducted by Yang et al. tested bronchial brushing of patients with lung cancer and 
of benign lung disease for mRNA expression levels via real-time PCR. (129) They detected 
the levels of mRNA to be increased in the lung cancer group and the difference to the control-
group was statistically significant. 
Ciotti et al. analyzed lung tumor tissue as well as neighboring healthy tissue from the same 
patients from Italy for HPV E6 and E7 oncogenes and their transcripts. (39) Of the included 
38 cases eight were positive for HPV DNA (21 %). Detection of HPV oncogene transcripts 
was done only on fresh tissue of HPV 16 positive cases. The E7 transcript was found in all 
but one case while in two rounds of amplification for E6 transcript only four patients were 
detected to be positive. All but one of the tumor specimens tested for transcripts contained 
either E6 or E7 transcripts. In one patient no viral transcripts was detected which could mean 
that in this case the detection of HPV DNA was accidental. 
In future studies PCR for HPV transcripts to further evaluate whether the detected HPV 
prevalence is accidental or if in fact viral oncogenes are expressed. 
 
Comparison with other systematic reviews and meta-analysis 
 
Several systematic reviews and meta-analysis have been done concerning HPV prevalence in 
lung cancer. 
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A systematic review done in 2009 by Srinivasan on 44 studies evaluated the HPV prevalence 
of HPV type 16 and 18 in primary lung cancer including studies using PCR. (130) The 
detected prevalence for HPV 16 and HPV 18 was 7.1 % and 5.6 % respectively. The detected 
HPV prevalence ranged from 0 % to 78.3 %. In our own systematic review the prevalence for 
HPV 16 DNA was higher than for HPV 18 as well. But the prevalence was lower for both 
HPV 16 and HPV 18 (6.0 % vs. 3.2 %). They also analyzed whether the used PCR primers 
had an influence on the detected HPV prevalence. The studies using type-specific HPV 
primers resulted in higher HPV detection rates. In this study only HPV DNA was tested 
which is not sufficient to establish a causal relationship. 
Another meta-analysis tested HPV prevalence in lung cancer cases compared to a control 
group. (131) Nine studies met the inclusion criteria resulting in 1094 analyzed cases and 484 
controls. The detected HPV prevalence in the lung cancer cases was higher than in the control 
group, 37.57 % and 10.54 % respectively. The association between LC and HPV was 
statistically significant. In our analysis the HPV detection rates in both subgroups were lower, 
31.3 % and 5.4 %. Nonetheless the detected difference in the HPV prevalence was 
statistically significant as well. 
A study focusing on the HPV incidence in lung cancer analyzed 53 studies with a total of 
4508 cases total. (132) The overall HPV prevalence was higher than in our analysis (24.5 %), 
similar to our own analysis the HPV prevalence in Asia was the highest of the compared 
continents. The most prevalent high-risk HPV subtypes were 16, 18, 31 and 33. This is in 
concordance with the HPV subtypes most frequently detected in our own systematic review. 
In this study the detected heterogeneity between studies was high as well. They discussed that 
different detection methods or tissue processing methods might be the reason. Our subgroup 
analysis did not find a statistic significant difference between FFPE vs. fresh-frozen tissue and 
only studies using PCR were included. 
A systematic review and meta-analysis from 2017 researched HPV infection as a potential 
prognostic marker for lung adenocarcinomas. (133) The pooled hazard ratio did not show a 
significant correlation between HPV positivity and overall survival (OS). 
Another specific topic analyzed is a possible association between HPV in NSCLC and never 
smokers. (134) The included studies in this systematic review used PCR as HPV detection 
method. The HPV prevalence with NSCLC in never-smokers was 31.4 %. They also 
compared the HPV prevalence between smokers and never smokers on the different 
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continents. HPV prevalence was significantly higher in never smokers in Europe, while the 
HPV prevalence in smokers and never smokers was similar in Europe. 
Since HPV infection could be an important risk factor in women and never smokers most of 
all in East Asia Bae et al. analyzed the available literature focusing on HPV prevalence in 
female never smokers. (135) Four case-control studies were included and the results showed a 
significant effect on lung cancer in female never smokers. 
Overall the detected HPV prevalence in the other systematic reviews was similar to our own 
findings. (128, 136) 
 
Publication and methodical bias 
 
To avoid possible publication bias not only journal articles but also meeting abstracts, poster 
presentations and information from study registrations were included. Still it has to be 
assumed that there is unpublished information which could not be found and reviewed for 
inclusion. Negative results are less likely to be published which can distort the overall results. 
One of the disadvantages of including shorter publications such as poster presentations is that 
they usually do not provide a lot of details which does influence the information that can later 
be analyzed. For example the included patient samples might have been discussed in another 
study but this information might not be included in the provided abstract. As a last 
consequence this might lead to information counted multiple times. 
By including all languages and time periods a broad range of studies was detected. Even 
though the initial data bank research was done using English search vocabulary which might 
lead to publications not being detected if neither title nor abstract was included in an English 
version. Internet search engines are usually only check for Arabic letters which improves the 
chances of studies written in languages using Arabic letters compared to study e.g. using 
Chinese letters. 
Heterogeneity between the studies was high in our systematic review. The subgroup analysis 
did not provide an explanation. We tried to minimize methodical bias by only including 
studies that used PCR for HPV DNA as primary detection method. The decision to include 
studies using PCR was made because of its high sensitivity and specificity. (137) 
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 8. Conclusion 
 
In this systematic review conducted on 73 studies that provided information on HPV 
prevalence in primary lung cancer tissue examined by PCR the overall HPV prevalence 
detected was 13.6 %. This rate was lower than in most systematic reviews made. 
A possible explanation might be that only studies using PCR were included while studies 
using ISH are discussed to detect higher prevalence.  
The HPV prevalence was analyzed for Europe, Asia and The Americas since no studies from 
Australia or Africa met the inclusion criteria. The highest HPV prevalence was detected in 
Asia followed by The Americas and Europe. This is in concordance with the information 
available in the literature even though no explanation has been found to this day. A 
geographic distribution as well as an ethnic component to HPV infection in lung cancer have 
been discussed. 
In a subgroup analysis researching HPV 16 and 18 prevalence in the three continents of which 
studies were included the difference was statistically significant in all of them. HPV 16 
prevalence was higher on all three continents. Overall HPV prevalence 16 and 18 was 6.0 % 
and 3.2 % respectively which was statistically highly significant as well (p<0.01). 
In our review HPV detection was more strongly associated with SCC than with AC. The 
difference was statistically significant. (18.6 % vs. 9.6 %, p<0.01) 
Even though the tissue processing method (FFPE vs. fresh frozen) did not result in a statistical 
difference in the detected HPV prevalence the time-period in which the analysis was made 
(1990s vs. 21st century) resulted in a statistically highly significant difference in the HPV 
prevalence that was detected (p=0.9 vs. p<0.01 respectively). 
The difference between HPV prevalence in the cancer and the control group in our analysis 
was statistically highly significant (31.3 % vs. 5.4 %, p<0.01) This result has been found in 
other systematic reviews as well which has led many authors to discuss a possible association 
between primary lung cancer and HPV infection. 
In the last 20 years lung cancer therapy has constantly developed. Targeted therapies and 
immunotherapy have not only improved the overall survival rates but have also changed the 
reality of cancer therapy for patients with more treatment being done by oral medication or in 
 - 69 - 
 
an ambulant setting. Also the side effects that have to be expected during these therapies are 
different and often more manageable. 
Still lung cancer has a very high mortality rate and is often diagnosed in a very late tumor 
stage. HPV infection as a modifiable risk factor has been discussed for a while now and since 
a vaccination is available some authors discuss a possible indication not only for young girls 
but also for young boys. A causal connection has not yet been made between lung cancer and 
HPV infection but since it has been between HPV infection and anogenital and other cancers 
Australia has established the National HPV Vaccination Program. It provides free vaccination 
in schools for both boys and girls aged 12-13 years. Since 2018 HPV vaccination for boys is 
recommended in Germany as well. 
Still the most important modifiable risk factor for lung cancer is smoking. Therefore smoking 
cessation has to remain one of the most important goals in lung cancer prevention. 
Mechanisms behind lung cancer development are still not fully understood. Neither are there 
established screening methods that allow earlier diagnosis. 
The information in our systematic review and in other publications suggests that HPV 
infection could play a role in lung cancer development but many questions are still 
unanswered. 
Most of the studies published used PCR on HPV DNA to determine the HPV prevalence in 
primary lung cancer specimens. Proof of HPV DNA in tumor samples is not enough evidence 
to prove a causal relationship between HPV and lung cancer development. One way to collect 
further information is to test for oncoprotein expression or mRNA. Another way is to confirm 
that HPV DNA is in fact integrated into the tumor genome. Only few studies using these 
methods have been done and more data will have to be gathered before a definitive decision 
can be made.  
Another point that can not yet be answered is why there seems to be a geographic difference 
in HPV prevalence in lung cancer. All of the published systematic reviews and meta-analysis 
published found the highest HPV prevalence in Asia which is in concordance with our own 
results. No explanation for this has been found. 
Some studies have discussed whether HPV is not an independent risk factor for lung cancer 
but a co-factor. In many studies HPV is more strongly related with SCC which is known to 
have a strong correlation with smoking. The very low detection of HPV in SCLC which has a 
very strong correlation with smoking behavior as well can be considered as a 
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counterargument. In contrast other studies have found a very high HPV prevalence in 
nonsmoking females with adenocarcinoma. 
Many different possible infection routes have been discussed. Based on todays knowledge 
HPV infection does not cause viremia even though that seems to be the most likely way of 
infection. Because of the given anatomy a direct infection of the bronchial epithelium seems 
unlikely. The way in which HPV enters host cells has not yet been fully understood either. 
Further research should be done on the large heterogeneity of HPV prevalence worldwide. 
Some of the possible influencing factors might be e.g. different PCR protocols, different PCR 
primers used or differences in the host factors. 
In conclusion further research has to be done most of all to examine the causality of HPV 
prevalence in lung cancer. 
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Table 20: Included Case-Control studies 
 
 Author Year No. 
Cases 
No. 
pos. 
Cases 
HPV 
prevalence 
Cases 
No. 
controls 
No. 
controls 
positiv 
HPV 
prevalence 
controls 
 Carpagnano, 
G.E. (38) 
 
2011 
 
89 12 16.4% 68 0 0% 
 Cheng, 
Y.W. (61) 
 
2004 
 
141 54 38.3% 60 1 1.% 
 Cheng, Y. 
W. (62) 
 
2001 141 77 54.6% 60 16 26.7% 
 Eberlein-
Gonska, M. 
(41) 
 
1992 55 3 5.5% 15 0 0% 
 Fan, X. (63) 
 
2015 262 22 8.4% 19 0 0% 
 Galvan, A. 
(42) 
 
2012 85 0 0% 100 0 0% 
 Gatta, L.B. 
(43) 
 
2012 50 2 4.0% 23 2 4.3% 
 Li, Q. (79) 
 
1995 50 16 32.0% 22 0 0% 
 Lu, Y. (81) 
 
2016 72 33 45.8% 54 2 3.7% 
 Nadji, S. A. 
(83) 
2007 129 33 25.6% 89 8 9.0% 
 Robinson, 
L. A. (106) 
 
2016 70 9 30.0% 10 1 10.0% 
 Wang, Y. 
(87) 
 
2008 313 138 44.1% 96 4 4.2% 
 Wang, Y. H. 
(88) 
 
2010 45 19 42.2% 16 0 16.0% 
 Yu, Y. (91) 
 
2015 180 100 55.6% 110 7 7.3% 
 Zhang, M. 
(92) 
 
2009 68 30 44.1% 12 1 8.3% 
Total   1750 548 31.3% 754 41 5.4% 
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Table 21: Included studies using FFPE processed tissue 
 
 Author Year No. Cases No. pos. Cases HPV prevalence 
 Aguayo, F. 
(59) 
2010 60 8 13.0% 
 Aguayo, F. 
(94) 
 
2007 69 20 29.0% 
 Baba, M. 
(60) 
2010 57 11 19.3% 
 Bohlmeyer, 
T. (96) 
 
1998 34 2 5.9% 
 Cardona, 
A.F. (97) 
 
2013 132 52 39.4% 
 Carlson, J. 
W. (98) 
 
2007 12 0 0% 
 Carpagnano, 
G.E. (38) 
 
2011 89 12 16.4% 
 Castillo, A. 
(99) 
 
2006 36 10 28.0% 
 Fan, X. 
(63) 
2015 262 22 8.4% 
 Garcia 
Falcone, 
M.M. (100) 
 
2017 40 10 25.0% 
 Gatta, L.B. 
(43) 
 
2012 50 2 4.0% 
 Goto, A. 
(64) 
 
2011 304 24 7.9% 
 Halimi, M. 
(65) 
 
2011 30 3 10.0% 
 Hartley, 
C.P. (66) 
 
2015 20 0 0% 
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 Henning, 
E.M. (45) 
 
1999 22 3 13.6% 
 Hirayasu, T. 
(67) 
 
1996 73 44 60.3% 
 Hiroshima, 
K. (68) 
 
1999 22 1 4.5% 
 Ilahi; N. E. 
(69) 
 
2016 9 1 11.1% 
 Isa, S.I. (70) 
 
2015 96 1 1.0% 
 Jafari, H. 
(73) 
 
2013 50 9 18.0% 
 Kato, T. 
(75) 
 
2012 42 7 16.7% 
 Kawaguchi, 
T. (76) 
 
2016 876 3 0.3% 
 Lee, J. E. 
(78) 
 
2016 233 0 0% 
 Lin, T. S. 
(80) 
 
2005 57 29 50.9% 
 Lu, Y. (81) 
 
2016 72 33 45.8% 
 Miasko, A. 
(47) 
 
2001 40 4 10.0% 
 Miyagi, J. 
(82) 
 
2001 121 41 33.9% 
 Nadji, S. A. 
(83) 
 
2007 129 33 25.6% 
 Pillai, R. N. 
(104) 
 
2013 208 32 14.9% 
 Rezazadeh, 
A. (105) 
 
2008 16 4 25.0% 
 Sarchianaki, 
E. (51) 
 
2014 100 19 19.0% 
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 Spandidos, 
D. A. (53) 
 
1996 99 15 15.0% 
 Suh, J. H. 
(107)  
2010 48 1 2.0% 
 Van 
Boerdonk, 
R. A. A. 
(55) 
 
2013 211 0 0% 
 Welt, A. 
(57) 
 
1997 38 0 0% 
 Xing, L. Q. 
(89) 
 
1993 49 7 14.2% 
 Yanagawa, 
N. (108) 
 
2013 336 5 1.5% 
 Yang, Y 
(90) 
 
1998 50 13 26.0% 
 Yu, Y. (91) 
 
2015 180 100 55.6% 
 Zhang, J. 
(139) 
 
2010 104 18 17.3% 
Total   4476 599 13.4% 
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Table 22: Included studies using fresh frozen tissue 
 
 Author Year No. Cases No. pos. Cases HPV prevalence 
 Coissard, 
C.J. (40) 
 
2005 218 4 1.8% 
 Galvan, A. 
(42) 
 
2012 85 0 0% 
 Guliani, L. 
(44) 
 
2007 78 10 12.8% 
 Iwakawa, R. 
(72) 
 
2010 297 0 0% 
 Jain, N. (74) 
 
2005 40 0 0% 
 Joh, J. (101) 
 
2010 30 5 16.7% 
 Ogura, H. 
(84) 
 
1993 29 3 10.3% 
 Robinson, 
L. A. (106) 
 
2016 70 9 30.0% 
 Sagerup, C. 
M. T. (50) 
 
2014 334 13 3.9% 
 Shamanin, 
V. (52) 
 
1994 85 0 0% 
 Thomas, P. 
(109) 
 
1995 31 5 16.0% 
 Wang, Y. 
(87) 
 
2008 313 138 44.1% 
 Wang, Y. H. 
(88) 
 
2010 45 19 42.2% 
 Zafer, E. 
(58) 
 
2004 40 2 5.0% 
 Zhang, M. 
(92) 
 
2009 68 30 44.1% 
Total   1763 238 13.5% 
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Table 23: Included studies conducted in the 1990s 
 
 Author Year of 
publication 
Time of 
research 
No. Cases No. pos. 
Cases 
HPV prevalence 
 Baba, M. 
(60) 
 
2010 1994 - 
1996 
57 11 19.3% 
 Hirayasu, 
T. (67) 
 
1996 1993 73 44 60.3% 
 Hiroshima, 
K. (68) 
 
1999 1995 - 
1999 
22 1 4.5% 
 Miasko, A. 
(47) 
 
2001 1998 - 
1999 
40 4 10.0% 
 Miyagi, J. 
(82) 
 
2001 1995 - 
1997 
121 41 33.9% 
 Park, M. S. 
(85) 
 
2007 1995 - 
1998 
112 60 53.6% 
Total    425 161 37.9% 
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Table 24: Included studies conducted in the 21st century 
 
 Author Year of 
publication 
Time of 
research 
No. Cases No. pos. 
Cases 
HPV prevalence 
 Argyri, E. 
(37) 
 
2017 2013 - 
2015 
67 2 3.0% 
 Badillo-
Almaraz, I. 
(95) 
 
2013 2006 - 
2009 
39 16 41.0% 
 Fan, X. 
(63) 
 
2015 2004 - 
2010 
262 22 8.4% 
 Garcia 
Falcone, 
M.M. (100) 
 
2017 2006 - 
2016 
40 10 25.0% 
 Gatta, L.B. 
(43) 
 
2012 2005 - 
2010 
50 2 4.0% 
 Giuliani, L. 
(44) 
 
2007 2002 - 
2006 
78 10 12.8% 
 Halimi, M. 
(65) 
 
2011 2009 - 
2011 
30 3 10.0% 
 Hartley, 
C.P. (66) 
 
2015 2004 - 
2013 
20 0 0% 
 Ilahi; N. E. 
(69) 
 
2016 2012 - 
2014 
9 1 11.1% 
 Ito, N. (71) 
 
2014 2012 - 
2013 
901 2 0.3% 
 Jafari, H. 
(73) 
 
2013 2006 - 
2009 
50 9 18.0% 
 Jain, N. 
(74) 
 
2005 2003 - 
2004 
40 0 0% 
 Joh, J. 
(101) 
 
2010 2006 - 
2008 
30 5 16.7% 
 Kato, T. 
(75) 
 
2012 2007 - 
2008 
42 7 16.7% 
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 Kawaguchi, 
T. (76) 
 
2016 2012 - 
2013 
876 3 0.3% 
 Lu, Y. (81) 
 
2016 2012 - 
2014 
72 33 45.8% 
 Pillai, R. N. 
(104) 
2013 2002 - 
2007 
208 32 14.9% 
 Podsiadlo, 
L. (49) 
 
2012 2011 33 1 3.0% 
 Robinson, 
L. A. (106) 
 
2016 2000 - 
2013 
70 9 30.0% 
 Sagerup, C. 
M. T. (50) 
 
2014 2006 - 
2011 
334 13 3.9% 
 Suh, J. H. 
(107) 
 
2010 2003 - 
2008 
48 1 2.0% 
 Syrjanen, 
K. (54) 
 
2012 2008 - 
2010 
77 4 5.2% 
 Wang, Y. 
H. (88) 
 
2010 2008 - 
2010 
45 19 42.2% 
 Yanagawa, 
N. (108) 
 
2013 2001 - 
2008 
336 5 1.5% 
 Yu, Y. (91) 
 
2015 2012 - 
2014 
180 100 55.6% 
 Zhang, M. 
(92) 
 
2009 2006 - 
2007 
68 30 44.1% 
Total    4005 339 8.5% 
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Vergleichender Literaturwissenschaft an der Johannes Gutenberg-
Universität, Mainz 
März 2009: Allgemeine Hochschulreife 
SS 2010 - SS 2012: Medizinstudium an der Johannes Gutenberg-Universität, Mainz 
WS 12/13 - SS 17: Medizinstudium an der Universität Regensburg 
Sept. 2017 -  Sept. 2019: Ärztin in Weiterbildung in der Klinik für Innere Medizin II, 
Abteilung für Pneumologie 
Oktober 2019: Beginn der Tätigkeit als Ärztin in Weiterbildung in der Klinik für 
Chirurgie 
 
